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PREAMBLE
Our mission was to develop evidence-based guidelines for
the prevention and treatment of perioperative/postoperative
atrial fibrillation and flutter (POAF) for thoracic surgical
procedures. Sixteen experts were invited by the American
Association for Thoracic Surgery (AATS) leadership: 7 car-
diologists and electrophysiology specialists, 3 intensivists/
anesthesiologists, 1 clinical pharmacist, joined by 5
thoracic and cardiac surgeons who represented AATS (see
Online Data Supplement 1 for the list of members and
Online Data Supplement 2 for the conflict of interest decla-
ration online).
Methods of Review
Memberswere taskedwithmaking recommendationsbased
on a review of the literature, with grading the quality of the ev-
idence supporting the recommendations, and with assessing
the risk-benefit profile for each recommendation. The level
of evidence was graded by the task force panel according to
standards published by the Institute of Medicine (Table 1).
For the development of the guidelines we followed the recom-
mendations of The Institute of Medicine (IOM) 2011Clinical
Practice Guidelines We Can Trust: Standards for Developing
Trustworthy Clinical Practice Guidelines; www.iom.edu/
cpgstandards.1Effortsweremade tominimize repetitionof ex-
isting guidelines2-4; ratherwe focused on new information and
advances in diagnosis and therapy, and present these currentFrom the Department of Anesthesiology,a Perioperative Critical Care and Pain Med-
icine, Brigham andWomen’s Hospital and Harvard Medical School, Boston, Mass;
Department of Cardiovascular Medicine,b Heart and Vascular Institute, Depart-
ment of Molecular Cardiology, Lerner Research Institute Cleveland Clinic, Lerner
College of Medicine of Case Western Reserve University Cleveland Clinic, Cleve-
land, Ohio; Division of Cardiovascular Medicine,c Department of Medicine, Case
Western Reserve University, Cleveland, Ohio; Harrington Heart & Vascular Insti-
tute,d University Hospitals Case Medical Center, Cleveland, Ohio; Division of Car-
diovascular Diseases and Internal Medicine,e Department of Medicine, Mayo
Clinic College of Medicine, Rochester, Minn; Department of Pharmacy Practice,f
College of Pharmacy, Purdue University and Indiana University School of Medi-
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ment of Surgery, Brigham and Women’s Hospital and Harvard Medical School,
Boston, Mass; Division of Thoracic Surgery,i Department of Surgery, Mayo Clinic
College of Medicine, Rochester, Minn; Center for Heart and Vascular Care,j
Department of Medicine, University of North Carolina, Chapel Hill, NC; Division
The Journal of Thoracic and Carguidelines within the framework of the new IOM
recommendations. In order to meet these standards, most
societies (American Heart Association and AATS included)
initiated the revision2,3 of existing guidelines.
Task force subgroups were formed and tasked with pre-
paring a summary of the available literature for each sub-
topic. Literature searches were conducted using PubMed,
focused on articles published since 2000 except in rare cir-
cumstances. Both the summaries and original articles were
made available to each task force member via a shared
electronic folder. The subgroup summaries as well as the
original literature were presented and discussed at 9 sched-
uled teleconferences. The conferences were recorded. Arti-
cles were selected for inclusion based on consensus opinion
by task force members. Writing groups were formed to
develop the draft guidelines for each subtopic, with 3 to 7
members and a leader for each group. Group recommenda-
tions were submitted before being presented for discussion
and voting at a 1-day face-to-face conference.
Members were specifically asked to assess the applica-
bility of the available evidence to patients undergoing
thoracic surgery. All recommendations were subjected to
a vote. Acceptance for the final document required greater
than 75% approval of each of the recommendations.
A final draft was prepared by the chairman of the task
force and made available in a written form to each member
for final comments. Subsequently, the recommendations
were posted for public comments for AATS members (via
REDCap), and then peer reviewed by outside experts
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Clinical Guidelines Frendl et alThe following recommendations are based on the best
available evidence from thoracic surgery. When evidence
specific to thoracic surgery was not available, we extrapo-
lated from the cardiac surgical literature. In the absence
of direct evidence, we present the best expert opinion based
on cardiology/cardiac electrophysiology experience and
best practices.
An executive summary was prepared for publication in a
printed format; this more extensive guideline was prepared
for online publication with additional comments, data, and a
comprehensive list of references.
AATS Member Survey
Our survey of the AATS members (results presented in
Online Data Supplement 3) indicated the need for a guide-
line update and identified opportunities for improvement in
the areas of prevention, standards for postoperative electro-
cardiography (ECG) monitoring, and for the possible use of
novel oral anticoagulants.When asked how the AATS could
help members improve their practices; 29% of respondents
recommended ‘‘initiating studies,’’ whereas 58% recom-
mended that the AATS ‘‘issue guidelines’’ and promote uni-
form practices.
Target Audience and the Patient Population
These guidelines are intended for all noncardiac intratho-
racic surgeries and esophagectomies, as well as for patients
whose risk factors and comorbidities place them at interme-
diate to high risk for POAF, independent of the procedure.
In assessing the patient’s risk for POAF, it must be noted
that the risks posed by the procedure and by patient fac-
tors/comorbidities will likely be additive, if not synergistic.
Therefore, these factors should be evaluated in combination
during the preoperative assessment.
The target audience includes not only thoracic surgeons
and anesthesiologists but all providers who participate in
the care of thoracic surgical patients.
The following novel information is included in this 2014
document: (1) standardized definitions for atrial fibrillation
(AF) and (2) recommendations for: (a) ECGmonitoring, (b)
postdischargemanagement, (c) use of the new class of novel
oral anticoagulants (NOAC); and (d) obtaining cardiology
consultation. In addition, flow diagrams summarize the
strategies for acute and chronic management. Specific
drug recommendations and dosing tables are also included.EPIDEMIOLOGY OF POAF, ITS IMPACT ON
OUTCOMES, COST, AND MORBIDITY
AF, themost common sustained arrhythmia after pulmonary
and esophageal surgery, is a major, potentially preventable,
adverse outcome. POAF peaks on postoperative days 2 to 4,
and 90% to 98% of new-onset POAF resolves within 4 to 6
weeks. Postoperative atrial fibrillation has multiple negative
implications. In the acute setting, the tachyarrhythmia cane154 The Journal of Thoracic and Cardiovascular Surlead to hemodynamic instability, necessitating prompt inter-
vention.A sustained increased heart rate can result in heart fail-
ure, a less common but clinically devastating situation, the
incidence of which is not reported in the literature.
The incidence ofPOAFvarieswidely basedon the intensity
of surgical stress (Table 2, A5-17) and patient characteristics
(Table 2, B5,6,8,10,18-20). Some of the risk factors for AF such
as hypertension, obesity, and smoking, are modifiable,
whereas others, such as older age, Caucasian ancestry, and
male sex, are not.
Thromboembolic events such as stroke or acute limb
ischemia are the most serious and feared consequences of
AF. Studies have reported a wide range of the incidence
of stroke related to POAF, although the risk for cardiac
and thoracic surgery seems to be 50% to 200% higher
than for general surgery.10,21,22
Many studies show an increase in mortality in patients with
POAF6,10,15,16,23,24 although some studies have not shown
such an effect.13,25 Given that patients with other significant
comorbidities or who are undergoing more complex
operations are more likely to experience POAF, it is unclear
to what extent the arrhythmia itself contributes to mortality. It
is feasible that the contribution of POAF to mortality is more
significant for those patients with fewer other comorbidities,
however this independent effect is more difficult to measure
and has not been well reported in the literature.
POAF is associated with longer intensive care unit and
hospital stays, increased morbidity (including strokes/new
central neurologic events) with incidence of 1.3%-
1.7%10,21,22; and mortality (up to 5.6%-7.5%; RR 1.7-
3.46,10,15,16,23,24), as well as higher resource utilization.6,26
Multiple studies have consistently demonstrated an in-
crease in length of hospital stay in patients who develop
POAF, generally by a mean of 2 to 4 days.5,6,10,15,16,19,23,24
An analysis of the Society of Thoracic Surgeons (STS)
database by Onatis and colleagues10 demonstrated that, in
patients undergoing lobectomy or greater resection for lung
cancer, the presence of POAF lengthened hospital stay by a
median of 3 days. The cost of hospitalization is likewise
increased for patients who develop POAF, with an increase
reported in the literature anywhere from 30% to 68%.5,6,23
To some extent, this increase reflects comorbid conditions
that occur along with POAF, but POAF itself is associated
with an increase in cost. Vaporciyan and colleagues5 found
that for patients who developed POAF without any other
complications, the cost of care increased by more than
US$6000, representing a greater than 30% increase.
THE POSSIBLE MECHANISMS OF POAFAFTER
THORACIC SURGERY
The mechanisms that initiate and sustain AF, including
POAF, are complex and require both a vulnerable atrial
substrate27 and a trigger to initiate AF (Table 3). Today
they remain incompletely understood. The role of triggersgery c September 2014
TABLE 1. Size of treatment effect and level of evidence for its impact
Schema used to guide the grading of available published evidence and the expected effect of the interventions for their impact on patient outcomes (the arrow indicates the di-
rection of increased effect size). COR, Class of recommendation.
Frendl et al Clinical Guidelinesfrom the pulmonary veins and other atrial sites initiating
AF28 is well appreciated. However, it remains to be under-
stood why they occur and what exact mechanisms are essen-
tial for their propagation. The identified risk factors for the
development of sustained POAF are mostly identical to
those known to make the atrium vulnerable to development
of AF in the nonsurgical setting. They include several risk
factors that are associated with atrial fibrosis, such as
increasing age, atrial dilatation, myocardial ischemia, vol-
ume overload, and a history of heart failure.29-31 They also
include risk factors such as increased norepinephrine
levels and increased vagal tone, both of which shorten
atrial wavelength, the latter known to increase atrial
vulnerability to AF.32 Both adrenergic and vagal stimulationThe Journal of Thoracic and Carcan promote triggers that initiate AF.33 In addition, surgical
procedures are associated with local or systemic inflamma-
tion (such as pericarditis), an important risk factor affecting
thevulnerability of the atrial substrate to POAF.34 The extent
of pulmonary resection is another important risk factor for
development of POAF.7 The development of POAF is likely
to involve some or all of these mechanisms.
Insight into the mechanism of POAF can be gained by
examining what prophylactic therapies decrease the rate of
POAF occurrence after thoracic surgery. Higher norepineph-
rine levels were found in patients on preoperative b-blockers
who had their b-blocker therapy interrupted than in patients
not receiving a b-blocker at all. This was associated with a
significantly higher incidence of POAF.30,35diovascular Surgery c Volume 148, Number 3 e155
TABLE 2, A. Risk stratification of thoracic surgical procedures for their risk of POAF
Type of procedures
Risk of POAF by surgical procedures
Low risk procedures
(<5% incidence)
Intermediate risk procedures
(5%-15% incidence)
High risk procedures
(>15% incidence)
Intrathoracic/airway procedures
Minor procedures Flexible bronchoscopy with and
without biopsy
Photodynamic therapy
Tracheal stenting
Placement of thoracostomy tube or
PleurX catheter (CareFusion
Corporation, San Diego, Calif)
Pleuroscopy, pleurodesis,
decortication
Procedures with
moderate stress
Tracheostomy
Rigid bronchoscopy
Mediastinoscopy
Thoracoscopic wedge resection5,6
Bronchoscopic laser surgery
Thoracoscopic sympathectomy
Major procedures Segmentectomy5,6 Resection of anterior mediastinal
mass
Thoracoscopic lobectomy
Open thoracotomy for lobectomy5-11
Tracheal resection and
reconstruction/carinal resection
Pneumonectomy5-8,11-13
Pleurectomy8
Volume reduction/bullectomy
Bronchopleural fistula repair
Clagett window
Lung transplantation14-16
Esophageal procedures Esophagoscopy/PEG/esophageal
dilation and/or stenting
Laparoscopic Nissen fundoplication/
myotomy
Zenker diverticulectomy
Esophagectomy5,8,17
Other procedures Pericardial window
Thoracic surgical procedures were divided into low (<5%), moderate (5%-15%) and high (>15%) risk groups based on their expected incidence of POAF in order to facilitate
the preoperative risk stratification of patients. POAF, Postoperative atrial fibrillation; PEG, percutaneous endoscopic gastrostomy.
Clinical Guidelines Frendl et alDiltiazem therapy initiated in the early postoperative
period has been found to significantly reduce the rate of
POAF.36 This is believed to be related to its effects of
decreasing pulmonary vascular resistance. It is known that
pulmonary hypertension and dilatation of the right side of
the heart are associated with an increased incidence of
POAF.29 There is also the possibility that as a systemic
vasodilator, diltiazem could reduce preload and left atrial
pressures.33 The data on use of verapamil have been incon-
sistent with regard to decreasing the incidence of POAF.37
Magnesium has been consistently shown to decrease
the incidence of POAF after cardiac surgery, and the only
prospective, randomized study on patients undergoing
thoracic surgery also showed a significant decrease in the
incidence of POAF.35 The reason for its effectiveness is
uncertain.
In the presence of a vulnerable substrate, additional elec-
trophysiologic abnormalities (drivers) will sustain AF.e156 The Journal of Thoracic and Cardiovascular SurRECOMMENDATIONS AND REASONING
1. Recommend the Use of the Following Definitions
for the Diagnosis of POAF
Class I
1.1. Electro-physiologic definition/diagnosis: ECG record-
ings (1 or more ECG leads) that demonstrate the pres-
ence of characteristic ECG features of AF lasting at
least for 30 seconds or for the duration of the ECG
recording (if shorter than 30 seconds)2,38 (level of
evidence LOE C). Clinical symptoms may include
hypotension, dizziness, decreased urinary output,
fatigue, and so on.
1.2. Clinical definition/diagnosis: clinically significant
POAF (Table 4) is AF in the (intra- and) postoperative
setting that requires treatment with rate or rhythm
control agents, or requires anticoagulation, and/or ex-
tends the duration of hospitalization (LOE C). Clinicalgery c September 2014
Cl
TABLE 2, B. Known patient risk factors for and comorbidities that
increase the risk of POAF
Risk factors and comorbidities Thoracic surgery references
Modifiable risk factors
Hypertension 8,10,18
MI 19
VHD
Heart failure 5,6,20
Obesity 10
Obstructive sleep apnea
Smoking
Exercise
Alcohol use
Hyperthyroidism
Increased pulse pressure
Mitral regurgitation
LVH
Increased LV wall thickness
Nonmodifiable risk factors
Increasing age 5,6,8,10,19,20
African American (protective factor) 10
Family history
Genetic variants
Male sex 5,8,10,20
History of arrythmias 5,6
Derived from the 2014 American Heart Association Atrial Fibrillation Guidelines
and relevant literature for thoracic surgery. Patient risk factors and comorbidities
that were shown to increase the risk of atrial fibrillation (AF) are listed. Much of
this information was extracted from the general population, thoracic surgery–specific
references are listed when available. These risk factors/comorbidities should be as-
sessed in conjunction with the procedure-related risks of AF in order to determine
the true risk of POAF. MI, Myocardial infarction; VHD, valvular heart disease; LV,
left ventricle; LVH, left ventricular hypertrophy.
TABLE 3. Probable mechanisms contributing to POAF
Clinically meaningful AF requires the presence of both a trigger and a
vulnerable atrial substrate
Atrial substrate changes that facilitate AF
Sympathetic or parasympathetic stimulation
Atrial dilation or acute atrial stretch
Pericarditis
Fibrosis
Inhomogeneous dispersion of conduction abnormalities
Short wavelength (conduction velocity 3 ERP)
Other (like inflammation and oxidative stress)
In addition, a driver(s) is thought to be needed to sustain AF in the
vulnerable substrate
Rapidly firing ectopic focus (atrial or other)
Reentrant circuit(s) of short cycle length (ordered reentry)
Potential role, if any, of multiple reentrant wavelets (random reentry)
AF, Atrial fibrillation; ERP, effective refractory period.
Frendl et al Clinical Guidelinessymptoms may include hypotension, dizziness,
decreased urinary output, fatigue, and so on.
We recommend that both electrophysiologically docu-
mented AF and clinically diagnosed AF be included in
the clinical documentation and reported in the clinical
trials/studies.
2. Physiologic (ECG) Monitoring of Patients at Risk
for POAF
Recommendations for ECGmonitoring of patients at risk
for POAF are presented in Table 5.
Class I
2.1. Patients should be monitored with continuous ECG
telemetry postoperatively for 48 to 72 hours (or less
if their hospitalization is shorter) if:
2.1.1. They are undergoing procedures that pose inter-
mediate (5%-15% expected incidence of AF) or
high (>15%) risk for the development of postop-
erativeAF or have significant additional risk fac-
tors (CHA2DS2-VASc 2) for stroke (LOE C).
2.1.2. They have a history of preexisting or periodic
recurrent AF before their surgery. These patientsThe Journal of Thoracic and Carshould also receive ECG monitoring in the im-
mediate preoperative period if procedures (eg,
epidural catheter or other regional anesthesia
blocks) are performed (LOE C).
Class IIa
2.2. Not using routine ECG telemetry is reasonable for pa-
tients who undergo low-risk (<5% expected incidence
of AF) procedures, and have neither a previous history
of AF nor significant risk for stroke (based on
CHA2DS2-VASc score), and have no relevant
comorbidities (such as heart failure or previous stroke)
(LOE C).diass I
2.2.1. If patients exhibit clinical signs of possible AF
while not monitored with telemetry, ECG re-
cordings to diagnose POAF and ongoing telem-
etry to monitor the period of AF should be
immediately implemented (LOE C).3. Rate Control and Antiarrhythmic Drugs,
Mechanism of Action, Side Effects, and Limitations
A detailed description of the drugs used for the manage-
ment of rate (Table 6) or rhythm control (Table 739), their
mechanism of action, side effects, and limitations are
discussed here. Dosing information is also presented in
Tables 6 and 7.
Recommendation
Class IIa
3.1. To optimize the efficacy and safety of amiodarone, it is
reasonable to exercise caution when selecting its doses
or intravenous versus oral route, because cases of acute
respiratory distress syndrome (ARDS) have been re-
ported following pneumonectomy with cumulative
intravenous doses more than 2150 mg40 (LOE C).ovascular Surgery c Volume 148, Number 3 e157
TABLE 4. Recommended definitions for the diagnosis of POAF
Definitions COR
Electrophysiologic
definition/diagnosis
ECG recordings (1 or more ECG
leads) with ECG features of AF
lasting at least for 30 seconds or
for the duration of the ECG
recording (if<30 seconds)
(LOE C)
I
Clinical definition/
diagnosis
Clinically significant POAF:
intra- and postoperative AF
requiring treatment, or
anticoagulation, and/or
extending the duration of
hospitalization (LOE C)
I
These measures should be included in the clinical documentation and reported in the
clinical trials/studies. POAF, Postoperative atrial fibrillation; ECG, electrocardiog-
raphy; COR, class of recommendation; LOE, level of evidence; AF, atrial fibrillation.
Clinical Guidelines Frendl et alReasoning
3.2. Rate control agents: their mechanisms of action
and side effects
3.2.1. b-Blockers
b-Blockers are Vaughan Williams class II antiar-
rhythmic agents that inhibit sympathetic nervous
system activity and slow the rate of phase IVTABLE 5. Recommendations for physiologic (ECG) monitoring
Recommendations for monitoring COR
Patients should be monitored with continuous ECG
telemetry postoperatively for 48-72 h (or less if their
hospitalization is shorter) if:
 they are undergoing procedures that pose high
(>15% expected incidence of AF) or intermediate
(5%-15%) risk for POAF or
 they have significant additional risk factors
(CHA2DS2-VASc>2) for stroke (LOE C)
 they have a history of preexisting or periodic
recurrent AF before their surgery
These patients should also receive ECG monitoring
in the immediate preoperative period if procedures
(epidural catheter, regional anesthesia blocks, and
so forth) are performed (LOE C)
I
Not using routine ECG telemetry is reasonable for
patients who
 undergo low risk surgery (<5% expected incidence
of AF) and
 had no previous history of AF, or
 have no significant risk for stroke and
 have no relevant comorbidities (eg, heart failure or
previous stroke) (LOE C)
IIa
If patients exhibit clinical signs of possible AF while
not monitored with ECG telemetry, ECG
recordings to diagnose POAF and continuous
telemetry to monitor the period of AF should be
immediately implemented (LOE C)
I
ECG, Electrocardiography; COR, class of recommendation; AF, atrial fibrillation;
POAF, postoperative atrial fibrillation; LOE, level of evidence.
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e158 The Journal of Thoracic and Cardiovascular Surgerrepolarization, thus slowing the discharge from
the sinus node.41 This antiadrenergic activity in-
hibits the renin-angiotensin-aldosterone system,
inhibits apoptosis, and reduces hyperphos-
phorylation of calcium-releasing channels.42
Metoprolol and atenolol are relatively selective
b-1 receptor antagonists (primarily affecting
cardiac tissue) and inmoderate doses have less ef-
fect on the b-2 receptors in smoothmuscle cells in
the vasculature and bronchial tree. Propranolol
and esmolol are nonselective, and carvedilol is
nonselective and possesses a-receptor blocking
activity.
Intravenous administration of metoprolol, pro-
pranolol, and esmolol reduces ventricular
response in patients with AF within 5 minutes
of administration,43 and both intravenous and
oral regimens attain resting and exercise rate
control, variably defined, in 68% to 75% of pa-
tients.44-47 Rate-lowering efficacy varies with
acuity and cardiac function and is enhanced
with digoxin.45,46
Themajor adverse effects ofb-blockers are bron-
chospasm in patients with asthma, particularly if
the asthma is not well controlled; worsening of
symptoms in patients with severe peripheral
arterial disease; hypotension; and worsening ofBLE 6. Commonly used rate control agents
Drug Recommended doses
Significant limitations
and known side effects
tiazem 0.25 mg/kg IV loading dose
over 2 min, then 5-15 mg/
h IV continuous infusion
Hypotension
Bradycardia
Heart failure exacerbation
oxin 0.25 mg IV repeated every
2-4 h to a maximum dose
of 1.5 mg over 24 h
Nausea, vomiting, anorexia
Confusion
AV block
Ventricular arrhythmias
Accumulates in acute
kidney injury/chronic
kidney disease
olol 500 mg/kg IV bolus over 1
min, then 50-300 mg/kg/
min IV continuous
infusion
Bradycardia
Hypotension
Bronchospasm
Heart failure exacerbation
toprolol 2.5-5.0 mg IV bolus over 2
min; maximum 3 doses
Bradycardia
Hypotension
Bronchospasm
Heart failure exacerbation
iodarone 150-300 mg IVover 1 h,
followed by 10-50 mg/h
IV continuous infusion
over 24 h
Bradycardia
QT interval prolongation
Pulmonary toxicity has not
been demonstrated at this
dose
ailed information in section 3 and in references 2 and 3. IV, Intravenous; AV,
ventricular.
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TABLE 7. Commonly used antiarrhythmic agents
Drug Recommended doses
Significant limitations and
known side effects Ref
Procainamide Conversion to sinus rhythm: 20-50 mg/min IV
continuous infusion until AF terminated,
hypotension occurs, or QRS duration prolonged by
50%, or cumulative total dose of 15 mg/kg reached
Alternative dose: 100 mg IV every 5 min until AF
terminated or other conditions as listed above are
met
If available orally, could be used for maintenance
Hypotension
QT interval prolongation
Torsades de pointes
Contraindicated in patients with heart failure with
reduced left ventricular ejection fraction
Contraindicated in patients with pretreatment QTc
interval>470 ms (men) or 480 ms (women)
39
Flecainide Conversion to sinus rhythm: 200-300 mg single
oral dose
Maintenance of sinus rhythm: 50-150 orally once
every 12 h
Dizziness
Blurred vision
Sinus bradycardia
AV block
Contraindicated in patients with heart failure with
reduced left ventricular ejection fraction
Contraindicated in patients with coronary artery
disease/structural heart disease
2,3
Propafenone Conversion to sinus rhythm: 450-600 mg single oral
dose
Maintenance of sinus rhythm: 150-300 mg orally every
8 h (immediate release); 225-425 mg orally every
12 h (extended release)
Dizziness
Blurred vision
Sinus bradycardia
AV block
Contraindicated in patients with heart failure with
reduced left ventricular ejection fraction
Contraindicated in patients with coronary artery
disease/structural heart disease
2,3
Amiodarone Prophylaxis: 300 mg IV bolus, then 600 mg orally
twice daily for 3-5 d
Treatment: 150 mg IVover 10 min; then 1 mg/min IV
continuous infusion for 6 h; the 0.5 mg/min IV
continuous infusion for 18 h or change to oral
administration at 100-400 mg daily
Bradycardia
QT interval prolongation
Pulmonary toxicity has not been demonstrated at this
dose
Bradycardia
Hypotension
QT interval prolongation
Pulmonary toxicity has occurred at cumulative IV
doses>2150 mg in patients undergoing
pneumonectomy
2,3,96
Dofetilide Not ideal for conversion to sinus rhythm in the
postoperative setting; may take 2-3 d to convert to
normal sinus rhythm, which would require
commitment to anticoagulation
Maintenance of sinus rhythm: calculated CrCl 20-40
mL/min: 125 mg orally once every 12 h
Calculated CrCl 40-60 mL/min: 250 mg orally once
every 12 h
Calculated CrCl>60 mL/min: 500 mg orally every 12 h
QT interval prolongation
Torsades de pointes
Risk of torsades de pointes is greater in patients with
heart failure
Dose adjustment is important in patients with acute
kidney injury or chronic kidney disease
Contraindicated in patients with calculated CrCl<20
mL/min
Contraindicated in patients with pretreatment QTc
interval>470 ms (men) or 480 ms (women)
Monitor ECGs 2 h after doses, telemetry for at least 3 d
2,3
Ibutilide Conversion to sinus rhythm:
Weight 60 kg: 1 mg IV administered over 10 min
Weight<60 kg: 0.01 mg/kg IV administered over
10 min
QT interval prolongation
Torsades de pointes
Risk of torsades de pointes greater in patients with heart
failure
Corvert prescribing
information
2006; Pfizer, Inc
(Continued)
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TABLE 7. Continued
Drug Recommended doses
Significant limitations and
known side effects Ref
If the AF does not terminate within 10 min of
completion of the first infusion, a second dose of
equal strength may be administered IVover 10 min
Not indicated for maintenance of sinus rhythm
Nonsustained ventricular tachycardia
Sinus pauses after AF conversion
Contraindicated in patients with pretreatment QTc
interval>470 ms (men) or 480 ms (women)
Sotalol Maintenance of sinus rhythm: 40-160 mg orally every
12 h
Dosing interval should be adjusted in patients with
acute kidney injury or chronic kidney disease:
If the calculated CrCl is 30-59 mL/min: administer
every 24 h
If the calculated CrCl is 10-29 mL/min: administer
every 36-48 h
Sinus bradycardia
AV block
QT interval prolongation
Torsades de pointes
Heart failure exacerbation
Risk of torsades de pointes greater in patients with heart
failure
Bronchospasm
Dose adjustment is important in patients with acute
kidney injury or chronic kidney disease
Use with extreme caution in patients with calculated
CrCl<10 mL/min and in patients undergoing
hemodialysis
Contraindicated in patients with pretreatment QTc
interval>470 ms (men) or 480 ms (women)
2,3
IV, Intravenous; AF, atrial fibrillation; AV, atrioventricular; CrCl, creatinine clearance; ECG, electrocardiography.
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e16heart failure symptoms in patients with decom-
pensated heart failurewith reduced ejection frac-
tion. Intravenous b-blockers should not be used
in patients with suspected accessory conduction
pathways.2,3,43 Profound bradycardia can
result from acute concomitant administration of
b-blockers and diltiazem or verapamil.
3.2.2. Diltiazem
Diltiazem is a nondihydropyridine calcium chan-
nel antagonist and class IV Vaughan Williams
agent. Diltiazem inhibits L-type calcium channels
invascular and conduction tissue, and especially in
nodal tissue.48 In addition, diltiazem affects
the transient outward and ultrarapid delayed recti-
fier potassium currents in atrial myocytes. Intrave-
nous diltiazem administered as a bolus and
continuous infusion can control ventricular
response in 70% to 90% of patients with the
recent-onset ofAF.Theonset of actionof diltiazem
is 2 to 7 minutes.43,49,50
Oral treatment with diltiazem in the Atrial Fibril-
lation Follow-Up Investigation of Rhythm Man-
agement (AFFIRM) trial was efficacious in
controlling rest and exercise heart rate in approx-
imately 60% of patients, and in 66% and 79% of
patients, respectively, when combined with
digoxin.45
Diltiazem canworsen heart failure in patients with
reduced ejection fraction, and can cause important
gastrointestinal adverse effects including ileus.0 The Journal of Thoracic and Cardiovascular SurgerDiltiazem must be used cautiously, especially
acutely, in patients concomitantly receiving
b-blockers, and is contraindicated in patients
with an accessory pathway.43
3.2.3. Digoxin
Digoxin inhibits sodium potassium adenosine
triphosphatase (ATPase), thereby increasing
intracellular sodium concentration leading to
increased intracellular calcium concentrations.
In addition, digoxin administration is associated
with an increase in baroreceptor sensitivity
disproportionate to hemodynamic improve-
ment, and imparts vagomimetic (parasympa-
thetic) effects. The vagomimetic effects of
digoxin occur at low serum concentrations and
contribute to decreasing sinus and atrioventric-
ular (AV) nodal conduction. At higher serum
concentrations, the parasympathetic effects
actually shorten the refractory period of nonno-
dal specialized conduction tissue.51
The onset of action of digoxin after intravenous
administration of 0.5 to 0.75 mg bolus doses is 30
minutes to 2 hours.52,53 With additional intra-
venous bolus doses of 0.25 mg every 2 to 6 hours
after the first dose, up to a total dose within 24
hours of 1.25 to 1.5 mg, 75% of patients with AF
can achieve rate control at rest.49,50 Exercise rate
control is achieved much less frequently, except
when digoxin is administered con-comitantly with
a b-blocker or calcium channel blocker.45y c September 2014
Frendl et al Clinical GuidelinesDigoxin should not be administered to patients
with suspected accessory pathways or obstructive
hypertrophic cardiomyopathy. The potential for
digoxin toxicity, including accelerated junctional
rhythm, accelerated ventricular escape rhythms
(sometimes heralded by regularization of the
longest R-R intervals), nausea, and visual symp-
toms is increased in the presence of hypokalemia,
hypomagnesemia, hypercalcemia, and concomi-
tant therapy with amiodarone, dronedarone or
verapamil.2,3,43 Propensity matched comparisons
in the AFFIRM trial do not suggest an increase
inmortality associatedwith chronic digoxin use.54
3.2.4. Amiodarone
Amiodarone is a Vaughan Williams class III agent
that inhibits inward potassium current, prolonging
the action potential. However, amiodarone also
has properties that could place it in the other 3
Vaughan Williams classes. It has antisympathetic
and calcium-blocking activity that leads to impor-
tant effects on the sinoatrial (SA) and AV nodes,
and the drug also has sodium channel–inhibiting
properties that increases the threshold for depolar-
ization.55,56
Intravenous amiodarone, administered as a bolus
and continuous infusion, has an effect on heart
ratewithin 4 hours that is similar to intravenous dil-
tiazem and intravenous digoxin, and improves ven-
tricular rate in 74% of patients with AF by 24
hours.50 Oral amiodarone can require days for
effective rate control to occur. Chronic oral amio-
darone therapy for rate control can have effects
similar to those of digoxin.2,3,57
Amiodarone is highly lipophilic, and intravenous
administration may exert effects that are different
from those following oral administration. Intrave-
nous amiodarone can be associated with AV
block, vasodilation, and hypotension. Intravenous
amiodarone should not be used in patients
who have a suspected accessory pathway.2,3
Pulmonary toxicity associated with high-dose
intravenous amiodarone is discussed in section
3.5.1.
Chronic administration of oral amiodarone can
be associated with pulmonary, hepatic, thyroid,
neurologic, cutaneous, and ocular toxicities.43
Amiodarone inhibits the metabolism of
warfarin and inhibits elimination of the new
oral anticoagulants. Amiodarone administration
can restore sinus rhythm so patients who
receive it after 24 to 48 hours of AF require
anticoagulation.The Journal of Thoracic and Car3.3. Antiarrhythmic medications (mechanisms of ac-
tion, side effects)
3.3.1. Amiodarone (see section 3.2.4)
3.3.2. FlecainidediovFlecainide is a VaughanWilliams class IC antiar-
rhythmic agent that is a potent inhibitor of fast
sodium conduction.41 Consequently, flecainide
decreases the maximum upstroke velocity and
amplitude of atrial, ventricular, andPurkinjefiber
action potentials.58 Flecainide may also inhibit
IKr current, and prolongs the duration of atrial
and ventricular action potential. In patients
without structural heart disease, oral flecainide
is relatively well tolerated; adverse effects
include dizziness (15%-20%) and visual abnor-
malities, including blurred vision and difficulty
in focusing (up to 15%), which can usually occur
during dose uptitration.59 However, in patients
with structural heart disease, flecainide is associ-
atedwithmore severe adverse effects. Flecainide
is associated with ventricular proarrhythmia in
this population; this proarrhythmia is not torsades
de pointes (TdP), but rather monomorphic ven-
tricular tachycardia. This proarrhythmia was the
likely cause of death associated with flecainide
(and encainide) in the Cardiac Arrhythmia Sup-
pression Trial (CAST),60 in which patients with
a history of myocardial infarction and symptom-
atic or asymptomatic ventricular ectopy (6 ven-
tricular premature depolarizations VPDs per
hour) were randomized to receive flecainide,
another Vaughan Williams class IC agent encai-
nide, or placebo for VPD suppression. Patients
randomized to receive therapy with flecainide
or encainide had an increased risk of totalmortal-
ity and an increased risk of nonfatal cardiac arrest
and death from arrhythmia. The risk of proar-
rhythmia associated with Vaughan Williams
class IC antiarrhythmic agents seems to be high-
est in patients with ventricular conduction delays
(QRS duration >120 milliseconds), structural
heart disease, ventricular scar tissue, or left
ventricular (LV) dysfunction.61 Consequently,
flecainide should be avoided in these patients.
In addition to the risk of proarrhythmia, flecai-
nide has potent negative inotropic activity, and
has been associated with worsening heart failure
in patients with coronary artery disease or pre-
existing heart failure (New York Heart Associa-
tion NYHA class II to IV and/or LV ejection
fraction<30%).59 Therefore, flecainide is con-
traindicated in patients with heart failure and
reduced ejection fraction.ascular Surgery c Volume 148, Number 3 e161
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United States, but is available in other countries.
In addition to the potential for ventricular proar-
rhythmia in patients with structural heart disease
and worsening of heart failure in patients with
LV dysfunction, intravenous flecainide may be
associated with hypotension.
3.3.3. Magnesium
Magnesium administered intravenously is often
referred to as a physiologic calcium channel
blocker, due to its antagonism of L- and T-type cal-
cium channels.62 Intravenous magnesium dimin-
ishes atrial automaticity63) and inhibits AV node
conduction.64 Intravenousmagnesium iswell toler-
ated; sinus bradycardia or AV block have been re-
ported with an incidence of approximately 3%.65
Intravenous magnesium may also cause hypoten-
sion (approximate incidence 4%).65 Transient
adverse effects including flushing, tingling, and
dizziness may occur in up to 17% of patients.65
3.3.4. Dofetilide
Dofetilide is a Vaughan Williams class III antiar-
rhythmic agent that inhibits IKr current,
66 and pro-
longs atrial and ventricular action potential
duration.67 Although dofetilide has been shown
to be effective for converting nonsurgical AF to si-
nus rhythm68 and for maintenance of sinus rhythm
in patients with nonoperative AF,69 it has not been
studied specifically for prevention or management
of AF after noncardiac thoracic surgery. As a
result of its propensity to inhibit IKr and prolong
ventricular repolarization, dofetilide may cause
TdP, with an incidence of approximately 1% in
patients with normal LV function.67 However,
the incidence increases to 3.3% in patients with
heart failure with reduced LV ejection fraction.70
To minimize the risk of TdP, dofetilide doses
must be appropriately adjusted for kidney dis-
ease.2,3
3.3.5. Dronedarone
Dronedarone is a Vaughan Williams class III
antiarrhythmic agent that was developed as a
potentially safer congener of amiodarone. Drone-
darone is similar to amiodarone in that it inhibits
multiple ion currents, including fast Naþ current,
IKr, acetylcholine-activated K
þ current, and L-
type calcium current.71 Dronedarone is also a
noncompetitive b-adrenergic inhibitor. Unlike
amiodarone, however, which possesses 2 iodine
atoms that compose 37% of its molecular weight,
dronedarone’s structure does not include iodine
atoms. In addition, the half-life of dronedarone
(13 to 31 hours) is much shorter than that of amio-2 The Journal of Thoracic and Cardiovascular Surgerdarone (10 to 40 days).71 Dronedarone’s primary
adverse effects include gastrointestinal distress
(16%), dizziness (9%), and bradycardia (3%).71
Dronedarone was associated with an increased
incidence of mortality in a randomized, double-
blind, placebo-controlled study.72 and therefore is
contraindicated in patients with NYHA class III
to IV heart failure, and in those patients with unsta-
ble NYHA class II heart failure.
Dronedarone has been shown to be effective for
maintenance of sinus rhythm in patients with
nonsurgical paroxysmal AF. Dronedarone is con-
traindicated in patients with permanent AF, due to
increased mortality associated with dronedarone
in that patient population.73 The efficacy of drone-
darone for maintenance of sinus rhythm in patients
with nonsurgical AF has not been investigated.
3.3.6. Ibutilide
Ibutilide is a Vaughan Williams class III antiar-
rhythmic agent that exerts its antiarrhythmic
activity via activation of slow inward sodium cur-
rent74 and inhibition of IKr.
75 Ibutilide is effective
for conversionof atrial flutter andfibrillation to sinus
rhythm.76 Ibutilide is not available in an oral dosage
form, and therefore is not used formaintenance of si-
nus rhythm. Ibutilide has been shown to be effective
for conversion to sinus rhythm of AFoccurring after
coronary artery bypass graft surgery.77 The efficacy
of ibutilide for conversion to sinus rhythm of AF af-
ter noncardiac surgery has not been investigated.
Theprimary adverse effect associatedwith ibutilide
is TdP, which occurs in 1% to 3% of patients. The
incidence of TdP is 2- to 3-fold higher in patients
with heart failure as a result of reduced ejection
fraction, which is a known risk factor for TdP. Ibu-
tilide may also cause nonsustained monomorphic
ventricular tachycardia in up to 8% of patients.
3.3.7. Procainamide
Procainamide is a VaughanWilliams class IA anti-
arrhythmic agent that exerts its antiarrhythmic ef-
fects through inhibition of fast sodium current as
well as inhibition of IKr. In addition, a primary
metabolite of procainamide, N-acetylprocaina-
mide, inhibits IKr current and contributes to the
overall antiarrhythmic activity of procainamide.
Procainamide is effective for conversion of
nonoperative AF to sinus rhythm.78 The efficacy
of procainamide for conversion to sinus rhythm
of AF after noncardiac thoracic surgery has not
been investigated. Procainamide is no longer
available in an oral dosage form, and therefore is
no longer indicated for maintenance of sinus
rhythm in patients with nonsurgical AF.y c September 2014
3Frendl et al Clinical GuidelinesThe primary adverse effects associated with intra-
venous procainamide are hypotension, QT interval
prolongation and TdP, and lengthening of the QRS
complex.
3.3.8. Propafenone
Propafenone is a Vaughan Williams class IC anti-
arrhythmic agent that is a potent inhibitor of
sodium conductance.79 Propafenone may also
inhibit the transient outward potassium current
(Ito) and the ultrarapid delayed rectifier potassium
(Ikur) current in atrial myocytes.
80 Propafenone is
effective for maintenance of sinus rhythm in
patients with nonoperative AF.81 In addition,
single-oral dose propafenone is effective for con-
version of nonsurgical AF to sinus rhythm.82 The
efficacy of propafenone for prophylaxis or man-
agement of AF after noncardiac thoracic surgery
has not been investigated.
Oral propafenone is well tolerated overall. Adverse
effects include dizziness and blurred vision. How-
ever, propafenone possesses negative inotropic
activity, and is contraindicated in patients with
heart failure due to reduced ejection fraction.2,3
In addition, propafenone is contraindicated in
patients with coronary artery disease or a history
of myocardial infarction. Although propafenone
was not studied in the CAST trial, the effects of
flecainide and encainide in that study are believe
to be to the result of potent sodium channel
inhibition, and contraindications in patients with
structural heart disease have been applied to
propafenone.
3.3.9. Sotalol
Sotalol is an adrenergic b-receptor blocking
agent83 that also prolongs atrial and ventricular ac-
tion potential duration via inhibition of IKr.
84 Sota-
lol is effective for reducing the incidence of
recurrent AF in patients with paroxysmal AF85
and after conversion to sinus rhythm.86 Sotalol
has not been shown to be effective for conversion
of AF to sinus rhythm. Sotalol has been used to
reduce the risk of AF after coronary artery bypass
graft (CABG) surgery.87 However, the efficacy of
sotalol for prophylaxis of AF after noncardiac
thoracic surgery has not been investigated.
.3.10. Quinidine
Quinidine is a Vaughan Williams class IA antiar-
rhythmic agent that inhibits sodium conduction88
as well as conductance of a variety of potassium
currents, including IKr, IKI, and Ito.
89 The use of
oral quinidine for management of AF has largely
been discontinued, because of evidence that
quinidine may increase mortality.2,3,90 QuinidineThe Journal of Thoracic and Carmay prolong the QT interval and cause TdP. The
efficacy of quinidine for prevention or
management of AF after noncardiac thoracic
surgery has not been evaluated.
3.4. Serum drug concentration monitoring
3.4.1. Digoxin
Serum drug concentration monitoring may be
warranted only if toxicity is of concern.diovDigoxin has a narrow therapeutic index, meaning
that serum concentrations required for efficacy
are similar to those that may cause toxicity.
When used for heart failure, the desired therapeu-
tic range is 0.5 to 0.9 ng/mL.91 The optimal
therapeutic range for digoxin for the management
of AF has not been established. The incidence
of adverse effects associated with digoxin
increases with serum concentrations greater than
2 ng/mL.92
During the management of AF after noncardiac
thoracic surgery,monitoring of serumdigoxin con-
centrations for assessment of efficacy is not neces-
sary, as a strong relationship between rate control
efficacy and serum digoxin concentration has not
been established. Determination of serum digoxin
concentration may be warranted if patients exhibit
symptoms of digoxin toxicity, including nausea,
vomiting, anorexia, or ventricular arrhythmias. If
a serum concentration is believed to be necessary,
the blood sample should be obtained at least
12 hours, and preferably 24 hours, after the previ-
ous digoxin dose, as a result of the prolonged tissue
distribution phase93(pp410-439); if the blood sample
is obtained less than 12 hours after the dose, the
serum concentration may be falsely increased, as
a result of incomplete distribution of digoxin
from serum to tissue.
To reduce the risk of digoxin toxicity in patients
receiving the drug for AF after noncardiac
thoracic surgery, serum digoxin concentration
monitoring may be warranted if digoxin therapy
must be continued for longer than 1 week, for
those patients who remain in AF after hospital
discharge. For patients with normal kidney func-
tion, the half-life of digoxin is approximately 36
hours; therefore, steady state serum concentra-
tions require approximately 1 week. Routine
determination of a steady state serum digoxin
concentration after 1 week of therapy is not
required in all patients. However, determination
of a serum digoxin concentration after 1 week
of therapy may be warranted in patients with
chronic kidney disease or acute kidney injury, or
in patients who are treated concomitantly with aascular Surgery c Volume 148, Number 3 e163
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amiodarone, dronedarone, propafenone, quini-
dine, and verapamil.93(pp410-439)
3.4.2. Procainamide: serum drug concentration
monitoring is not warranted
The suggested therapeutic range for procainamide
efficacy is 4 to 10 mg/L.93(pp440-462) However, this
therapeutic range was determined using suppres-
sion of ventricular premature depolarizations and
prevention of episodes of ventricular tachycardia.
Serum procainamide concentrations have not been
correlated with efficacy in AF, and therefore,
desired serum procainamide concentrations for ef-
ficacy in AF are unknown. Serum concentration
monitoring for intravenous procainamide for man-
agement of AF after noncardiac thoracic surgery is
not warranted. The risk of adverse effects associ-
ated with intravenous procainamide can be mini-
mized by terminating the loading dose of 20 to
50 mg/min continuous infusion if hypotension oc-
curs, QRS duration is prolonged by 50%, or a cu-
mulative intravenous dose of 17 mg/kg has been
administered.39
3.4.3. Amiodarone: serum drug concentration
monitoring is not warranted
Serum amiodarone concentration monitoring has
been performed during therapy for ventricular ar-
rhythmias. However, a relationship between
serum amiodarone concentrations and efficacy
for prevention or management of AF has not
been established. Similarly, a relationship be-
tween serum amiodarone concentrations and
most of the adverse effects of amiodarone, partic-
ularly those that occur during short-term therapy,
has not been established. Therefore, monitoring
of serum amiodarone concentrations during pro-
phylaxis or management of AF after noncardiac
thoracic surgery is not warranted. However, to
minimize the risk of pulmonary toxicity, it is rec-
ommended to keep total cumulative intravenous
amiodarone doses to less than 2150 mg.
3.4.4. Flecainide: serum drug concentration moni-
toring is not warranted
The therapeutic range for serum flecainide
concentrations is often cited as 0.3 to
2.5 mg/L.93(pp440-462) However, this therapeutic
range was developed using suppression of ventric-
ular premature depolarizations as an end point,
rather than efficacy for the management of AF. A
relationship between serum flecainide concentra-
tions and efficacy for prophylaxis or management
of AF, particularly that occurring after noncardiac4 The Journal of Thoracic and Cardiovascular Surgerythoracic surgery, has not been established. Serum
flecainide concentration monitoring for prophy-
laxis or treatment of AF after noncardiac thoracic
surgery is not warranted.3.5. Key limitations of drugs
3.5.1. Pulmonary toxicityAprimary concern regarding the administration of
intravenous amiodarone following lung resection
is pulmonary toxicity, specifically ARDS. This
concern was prominently identified by Van Mie-
ghem and colleagues,40 who initiated a study to
determine the comparative effectiveness of amio-
darone, verapamil, or placebo for prevention of
AF after pulmonary resection. The study was
terminated prematurely due a high incidence of
ARDS in amiodarone-treated patients, specif-
ically in patients who had undergone pneumonec-
tomy. At the time of discontinuation of the
amiodarone arm, the drug had been administered
to 32 patients, of whom 21 had undergone lobec-
tomy and 11 had undergone pneumonectomy.
No patients who underwent lobectomy developed
amiodarone-associated ARDS. In contrast, 3 of 11
patients (27%) in the amiodarone group who un-
derwent pneumonectomy developed ARDS. The
investigators recommended avoiding amiodarone
administration for patients undergoing pulmonary
resection.
Other investigators have administered intrave-
nous amiodarone to patients undergoing lung
surgery without adverse effects. In a prospective,
randomized, unblinded amiodarone prophy-
laxis,94 the incidence of ARDS among the 65
amiodarone-treated patients (of whom 40 under-
went lobectomy, 8 underwent bilobectomy, and
17 underwent pneumonectomy) was 0%. Barbe-
takis and colleagues95 administered intravenous
amiodarone to 43 patients for treatment of AF
after lung resection. No patients developed
ARDS; 21 of these patients underwent pneumo-
nectomy. Riber and colleagues96 conducted a
randomized, prospective, double-blind, placebo-
controlled study of amiodarone for prevention
of AF after lung resection. Only 2 patients of
the 122 who received amiodarone underwent
pneumonectomy; the remainder underwent
right-side lobectomy or bilobectomy. No patients
in this study developed ARDS or any pulmonary
toxicity.
One potential difference in patients undergoing
pneumonectomy in the Van Miegham study40
compared with these more recent trials94-96c September 2014
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dose administered. In the Van Mieghem study,
intravenous amiodarone was administered as a
bolus of 150 mg over 2 minutes, followed by a
continuous infusion of 1200 mg over 24
hours for 3 consecutive days, for a possible
cumulative intravenous amiodarone dose of 3750
mg. The 3 patients who developed amiodarone-
induced ARDS received cumulative intravenous
amiodarone doses of 2150, 3750, and 3350 mg
before discontinuation of therapy. In the more
recent studies, patients received a cumulative
intravenous amiodarone dose of 1050 mg, after
which oral amiodarone was initiated,94 or a
loading dose of 300 mg intravenous amiodarone
before switching to oral amiodarone.96 In the Bar-
betakis study,95 intravenous amiodarone was
administered as a loading dose of 5 mg/kg over
5 minutes, followed by 15 mg/kg for an undefined
time period. In addition, in the Van Miegham
study, the 3 patients who developed amiodarone-
associated ARDS underwent right-sided pneumo-
nectomy, which is associated with a higher risk of
postoperative ARDS than other types of lung
surgery.
Overall, administration of amiodarone at the dose
shown to be effective by Riber and colelagues96
(300 mg intravenous loading dose followed by
600 mg orally twice daily for 5 days) seems to
be safe and effective for prevention of AF after
pulmonary resection.
3.5.2. QT interval prolongation/torsades de pointes
Several of the drugs that may be used for prophy-
laxis or management of postoperative AF may
cause QT interval prolongation, and therefore
pose a risk for the life-threatening polymorphic
ventricular arrhythmia known as TdP.97 Drugs
that prolong the QT interval are generally those
that inhibit IKr, and include amiodarone, procaina-
mide, dofetilide, dronedarone, ibutilide, sotalol,
and quinidine. A Bazett-corrected QT (QTc) in-
terval greater than 500 ms markedly increases
the risk for drug-induced TdP.98 Patients
receiving a drug that prolongs the QTc interval
should have the QTc interval measured from a
rhythm strip or 12-lead ECG at least once daily
during therapy. In addition, because the occur-
rence of TdP is highly dependent on the presence
of other risk factors (female sex, hypokalemia,
hypomagnesemia, hypocalcemia, bradycardia,
heart failure, increased serum drug concentra-
tions),97,98 modifiable risk factors should be
corrected. Serum potassium, magnesium, andThe Journal of Thoracic and Cardicalcium concentrations should be maintained in
the normal range. Drug interactions leading to
increased concentrations of a QT interval–
prolonging drug should be avoided. Doses of
renally eliminated QT interval–prolonging drugs
(dofetilide, procainamide, sotalol) should be
appropriately adjusted for declining kidney
function. In addition, concomitant therapy with
other QT interval-prolonging drugs, particularly
noncardiovascular QT interval-prolonging drugs
(fluoroquinolone and macrolide antibiotics, azole
antifungal agents, antidepressants, antipsy-
chotics, many others)97 should be avoided or per-
formed cautiously.
3.5.3. Hypotension
Several drugs administered intravenously for
prophylaxis or management of postoperative
AF may cause hypotension, including diltiazem,
esmolol, metoprolol, procainamide, and amio-
darone. Drug-associated hypotension is more
likely to occur when patients are volume
depleted, which is often the case after thoracic
surgery. In the population with AF after coronary
artery bypass graft, hypotension associated with
intravenous diltiazem was more likely when
the pretreatment systolic blood pressure was
less than 115 mm Hg.99
3.5.4. Bradycardia
Drugs used for ventricular rate control can also
result in bradycardia through inhibition of sinus
node function or AV nodal conduction. These
drugs include amiodarone, propafenone, flecai-
nide, esmolol, metoprolol, sotalol, and diltia-
zem.97 The risk is higher when combinations of
sinus node or AV node-inhibiting drugs are used.
3.5.5. Exacerbation of heart failure with reduced LV
ejection fraction
Several drugs used for prophylaxis or treatment of
postoperative AF possess negative inotropic ac-
tivity and are contraindicated in patients with
heart failure with reduced LV ejection fraction.
These drugs include diltiazem, procainamide,
propafenone, and flecainide.4. Prevention Strategies and Their Efficacy
Recent evidence suggest that some prevention strategies
(avoiding b blockade withdrawal for those chronically on
those medications, correction of serum magnesium when
abnormal) may be effective for all patients for reducing
the incidence of POAF. By surveying the AATS member-
ship, we also found that many of these strategies are
currently underused (Figure 1).ovascular Surgery c Volume 148, Number 3 e165
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4.1. Recommended prevention strategies for all patients
Class I
4.1.1. Patients taking b-blockers before thoracic surgery
should continue them in the postoperative period
to avoid b-blockade withdrawal.3,38,100-104 (LOE
A).
Class IIb
4.1.2. Intravenous magnesium supplementation may
be considered to prevent postoperative AF
when serum magnesium level is low or it is
suspected that total body magnesium is
depleted.31,38,105 (LOE C).
Class III
4.1.3. Digoxin should not be used for prophylaxis
against AF.2,38,106-108 (LOE A).
4.1.4. Catheter or surgical pulmonary vein isolation
(at the time of surgery) is not recommended for
prevention of POAF for patients who have no
previous history of AF109 (LOE C).
4.1.5. Complete or partial pulmonary vein isolation at
the time of (even bilateral) lung surgery should
not be considered for prevention of POAF, as it
is unlikely to be effective109-111 (LOE B).
For those patients at increased risk for the develop-
ment of POAF, preventive administration of medi-
cations (diltiazem or amiodarone) may be
reasonable. However, these strategies may not be
useful for all thoracic surgical patients.
4.2. Recommended prevention strategies for intermedi-
ate to high-risk patientsClass IIa
4.2.1. It is reasonable to administer diltiazem to those
patients with preserved cardiac function who are
not taking b-blockers preoperatively in order to
prevent POAF2,36,112 (LOE B).
4.2.2. It is reasonable to consider the postoperative admin-
istration of amiodarone to reduce the incidence of
POAF for intermediate andhigh risk patients under-
going pulmonary resection2,17,94-96,113 (LOE A).
Class IIb
4.2.3. Postoperative administration of intravenous
amiodarone may be considered to prevent
POAF in patients undergoing esophagec-
tomy17,96,113,114 (LOE B).
4.2.4. Atorvastatin may be considered to prevent POAF
for statin-naive patients scheduled for intermedi-
ate- and high-risk thoracic surgical proce-
dures3,115-117 (LOE C).
4.3. Recommended prevention strategies for the highest-
risk patientse166 The Journal of Thoracic and Cardiovascular SurClass IIb
4.3.1. Left atrial appendage excision may be considered
at the time of extensive left lung surgery for pa-
tients with preexisting AF who are considered
too high a risk for anticoagulation in the perioper-
ative period2,38,118 (LOE C).
Reasoning
4.4. Prevention of postoperative AF
AF, the most common sustained arrhythmia after pul-
monary and esophageal surgery, is associated with
longer intensive care unit and hospital stays, increased
morbidity andmortality, and higher utilization of health
care resources.6,26 POAF also represents a major
potentially preventable adverse outcome. Several
randomized controlled studies and meta-analyses
have examined the efficacy of a variety of agents
including antiarrhythmics, b-blockers, and novel
agents such as magnesium and statins to prevent the
development of POAF in patients undergoing thoracic
surgery. However, it should be appreciated that there
is a dearth of data indicating that prophylactic therapy
for AF improves outcomes after thoracic surgery (eg,
stroke) and reduces length of hospital stay, and many
of the recommendations are extrapolated from the car-
diac surgery arena.
The recommendation to avoid withdrawal of b-
blockers in all patients undergoing thoracic surgery is
mainly derived from the cardiac surgery literature. Nat-
tel and colleagues100 showed that abrupt propranolol
withdrawal was associated with increased sensitivity
to isoproterenol, and a large meta-analysis of random-
ized studies confirmed that acute withdrawal of b-
blockers before cardiac surgery increases the risk of
developing POAF.103 There are only limited data sup-
porting the role of prophylactic b-blockers in patients
undergoing thoracic surgery.13,101,102 Although two of
these randomized studies showed a reduction in
POAF, there was a high incidence of hypotension and
bradycardia that limited the use of b-blockers in the
perioperative setting.119 There remains controversy in
the recent literature as to whether to initiate periopera-
tive b-blockers in patients who are not already taking
them. At recommended doses aimed at achieving a
target heart rate, b-blockers may cause significant post-
operative hypotension and stroke-related mortality.119
In randomized controlled trials, diltiazem has not
been associated with perioperative hypotension. The
ability of diltiazem to reduce AF after thoracic surgery
is moderate.36
To date, the best evidence for efficacy of AF prevention
in general thoracic surgery patients has been withgery c September 2014
FIGURE 1. Prevention strategies and their efficacy for postoperative atrial fibrillation (POAF). LOE, Level of evidence;PVI, pulmonary vein isolation; i.v.,
intravenous; LVEF, left ventricular ejection fraction; AF, atrial fibrillation.
Frendl et al Clinical Guidelinesamiodarone. An important issuewith any prevention ef-
forts is the acceptance of a recommended medication
by the responsible surgical team, particularly with a
drug like amiodarone that has potential for side effects.
The antiarrhythmic mechanism of amiodarone com-
bines varying degrees of class III antiarrhythmic activ-
ity, b-blockade, and calcium channel antagonism.
Slower postoperative heart rates with short-term use
and greater than moderate efficacy in reducing AF
may result in wider physician acceptance of amiodar-
one, although concerns regarding rare reports of pulmo-
nary toxicity with right lung resection or lung
transplantation may moderate its use (discussed in
more detail in section 3).
4.5. Pharmacologic therapies to prevent POAF
4.5.1. Amiodarone
Efficacy of amiodarone: Tisdale and colleagues94
showed that amiodarone 1.05 g given by contin-
uous intravenous infusion over the first 24 hours
after pulmonary resection and then 400 mg orally
twice daily for up to 6 days, reduced the rate of
POAF requiring treatment, 9 of 65 (14%) in
comparison with 21 of 65 (32%), in an untreated
control group. In a similar study, the same inves-
tigators17 showed that continuous infusion of
amiodarone 43.75 mg/h for 96 hours (total dose
4200 mg) was associated with a lower POAF
rate of 6 of 40 (15%) in patients undergoing
esophagectomy compared with 16 of 40 (40%)
in an untreated control group. The largest trial
to date by Riber and colleagues96 used a random-
ized, double-blind, placebo-controlled design of
amiodarone given by loading 300 mg intrave-
nously immediately when stable after surgery
followed by 600 mg orally twice daily for up toThe Journal of Thoracic and Cardiov5 days. They showed that amiodarone-treated pa-
tients had a rate of POAF (lasting>5 min) of 9%
(11 of 122), compared with placebo controls who
had a rate of 32% (38 of 120). A final study of
patients undergoing pulmonary resection random-
ized 2 groups of patients in a prospective, double-
blind design to either amiodarone (postoperative
intravenous loading 5 mg/kg, then 15 mg/kg for
48 hours intravenous infusion) or magnesium sul-
fate (preoperative loading of 80 mg/kg and then 8
mg/kg/h for 48 hours intravenous infusion after
surgery).113 This study showed that the incidence
of POAF (lasting>30 seconds) was 10% (21 of
219) with amiodarone and 13% (27 of 219) with
magnesium. None of these studies reported any
serious adverse effects caused by amiodarone
except occasional bradycardia.
Safety of amiodarone: In the nonsurgical popula-
tion, it is commonly accepted that amiodarone-
related pulmonary toxicity does not occur with
short-term (<1 month) exposure. Concerns about
amiodarone-related perioperative pulmonary
toxicity were raised 2 decades ago in a small ran-
domized study that was interrupted early because
3 right-sided pneumonectomy patients of a total
of 11 patients who received amiodarone for pre-
vention of POAF developed ARDS, whereas
none of the 21 patients undergoing lobectomy
and exposed to amiodarone developed this compli-
cation.40 The investigators acknowledged that
right-sided pneumonectomy in itself was a well-
established risk for ARDS, but nevertheless
cautioned on the use of amiodarone forAF preven-
tion after pulmonary resection. Since then, several
observational and more recent prospective ran-
domized trials failed to find a link between use ofascular Surgery c Volume 148, Number 3 e167
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e16amiodarone for AF prevention and ARDS immedi-
ately after pulmonary resection.17,94,96,113,114
Several other studies used amiodarone for acute
treatment of AF after general thoracic surgery,
and none of these reported amiodarone-related pul-
monary toxicity. Of 3 retrospective studies
describing risk and treatment ofAFafter lung trans-
plant, only 1 study120 reported an association be-
tween pulmonary toxicity and amiodarone use
and cautioned on the routine use of amiodarone af-
ter lung and heart-lung transplants.15,120
4.5.2. Diltiazem
Efficacy of diltiazem: A meta-analysis of
randomized controlled trials that evaluated calcium
channel blockers given immediately before, dur-
ing, or after CABG surgery or valve surgery
showed that these drugs reduced rates of myocar-
dial injury and supraventricular tachycardia
(SVT).112 In patients undergoing thoracic surgery,
there have been 3 prospective randomized trials
of nondihydropyridine calcium channel antago-
nists for the prevention of AF. Verapamil prophy-
laxis was used in a large, randomized, open-label
study of patients undergoing lobectomy or pneu-
monectomy using somewhat aggressive loading
(started within 1 hour of arrival in recovery, 10
mg over 10 minutes followed by 0.375 mg/min
over 30 minutes) and then by continuous infusion
(0.125mg/min for 3 days).37 This medical regimen
was associated with a nonsignificant reduction of
AF from 15% (15 of 99) in placebo patients to
8% (8 of 100), respectively. In a small, random-
ized, open-label study of patients undergoing stan-
dard or intrapericardial pneumonectomy, diltiazem
prophylaxis was associated with reduced overall
incidence of SVT in comparison with digoxin-
treated patients (0 of 21 vs 8 of 25,P<.005, respec-
tively).108 In a larger follow-up, randomized,
double-blind, placebo-controlled study of patients
undergoing lobectomy or pneumonectomy, diltia-
zem started within 1 hour of arrival in recovery,
0.15 mg/kg (loading while the patient was fasting
then 120mgorally twice a day for 14 days) reduced
the rates of postoperative atrial arrhythmias in com-
parisonwith placebo (25 of 167 [15%] vs 40 of 163
[25%], respectively, P ¼ .03).36
Safety of diltiazem: With the doses described in a
randomized open-label study of verapamil given
early after lobectomy or pneumonectomy, 14%
of the patients experienced hypotension and 9%
had bradycardia requiring temporary interruption
of the drug infusion.37 In contrast, mild transient
hypotension was reported in 4% (6 of 163) of8 The Journal of Thoracic and Cardiovascular Surgerdiltiazem-treated patients, especially early after
surgery, with resumption of diltiazem therapy
soon thereafter.36
4.5.3. Novel therapies to prevent postoperative AF
Inflammation and oxidative stress play an im-
portant role in the pathogenesis of AF.121 Several
studies have examined the role of statin therapy in
preventing POAF. One of the largest (n ¼ 200)
randomized studies evaluated the role of atorvas-
tatin, given 7 days before and 7 days after cardiac
surgery. Those patients who received the statin
demonstrated a 22% reduction in incidence of
POAF. Amar and colleagues115 conducted a
prospective study of 131 patients undergoing ma-
jor lung or esophageal surgery to evaluate the
relationship between C-reactive protein and
POAF. A secondary analysis in this study showed
that in the subset of patients receiving preopera-
tive statins, the risk of developing AF was almost
3-fold lower than in those not taking them. Two
meta-analyses of randomized studies examining
prophylactic statin therapy was performed that
involved more than 2200 patients.116-117 These
studies supported the role of statins in
preventing POAF in statin-naive patients under-
going high-risk cardiac and noncardiac surgery
or after acute coronary syndromes. Additional
randomized placebo-controlled studies will be
required before statin therapy can be recommen-
ded as a Class I or IIa indication to prevent
POAF in statin-naive patients undergoing moder-
ate to high-risk lung surgery. As in other patients
undergoing noncardiac surgery, most physicians
continue statin therapy preoperatively to avoid
withdrawal.
There is strong evidence supporting the use of
magnesium supplementation to prevent POAF in
patients undergoing cardiac surgery.105 In the
only prospective, unblinded randomized,
controlled trial (n ¼ 200) in patients undergoing
thoracic surgery, Terzi and colleagues31 demon-
strated that the incidence of postoperative atrial
tachyarrhythmias, mainly AF, was reduced from
23% to 11% in those patients treated with an
intravenous infusion of magnesium during the
perioperative period.
Three large randomized clinical trials have clearly
demonstrated that prophylaxis with digoxin does
not prevent and may in fact increase the incidence
of POAF in patients undergoing all types of
thoracic surgery.106-108 Although, acute digoxin
loading may be beneficial in controlling rapid
ventricular rates during AF in patients withy c September 2014
Frendl et al Clinical Guidelineshypotension, there is no place for digoxin
prophylaxis in patients undergoing thoracic
surgery.
4.5.4. Surgical prevention strategies
Cardiac surgery patients with preexisting AF who
undergo surgical pulmonary vein isolation (PVI)
and receive additional biatral linear lines of block
may achieve a 75% to 85% freedom from AF at
6 to 12 months, and the procedure adds on average
an additional 9 minutes to the surgery, without
perceptible safety risks, although possibly the pa-
tients have a slightly higher risk of needing a pace-
maker during the early postoperative period.122
Patients who undergo the equivalent of near-
complete PVI associated with bilateral lung trans-
plantation have a low incidence ofAF3 to6months
after the procedure.109 For patientswith preexisting
AF who are known to tolerate the arrhythmia
poorly or who have an increased bleeding risk on
anticoagulants, 2 questions arise: would PVI, bilat-
eral or unilateral, help prevent perioperative AF,
andwould operative left atrial appendage exclusion
lower perioperative thrombotic risk?
Multiple studies109-111 have shown that the
incidence of POAF is in the 20% to 40% range
even after double lung transplant, confirming
that this form of AF is related to inflammatory,
mechanical, and autonomic factors, in addition
to pulmonary vein triggers. Unilateral PVI is not
likely to be any more beneficial, and has a
distinct disadvantage beyond the perioperative
period.123
Excision of the left atrial appendage can be per-
formed safely, with efficacy rates approaching
87%, after a learning curve,118 but there are no
studies that show a reduction in perioperative
thrombotic events. The Left Atrial Appendage
Occlusion Study is ongoing. Data from the
Watchman124 and Prevail trials cannot necessarily
be extrapolated to operative left atrial appendage
exclusion, and neither of these studies involved
patients undergoing thoracotomy. Although the
alteration in left atrial compliance and filling pres-
sures after appendage exclusion may be small, the
effects may be different in a lung population that
may have a smaller atrial size than in a cardiac
valve surgery population.5. Treatment Strategies for POAF and Their Efficacy
The management of patients presenting with POAF
requires different strategies depending on their hemody-The Journal of Thoracic and Carnamic stability. Although some interventions are likely to
benefit all patients (see section 5.1), hemodynamically un-
stable patients will require urgent efforts for the restitution
of sinus rhythm (section 5.2). However, for stable patients
with POAF, the emphasis shifts to rate control strategies
(see details in section 5.3).2
Recommendations
5.1. Management strategies recommended for all pa-
tients with new-onset POAF (Figure 2)Class I
5.1.1. Reduce or stop catecholaminergic inotropic
agents if hemodynamics allow (LOE C).
5.1.2. Optimize fluid balance and maintain normal
electrolyte levels (LOE C).
5.1.3. Evaluate the presence of and treat all possible
correctable triggering factors. These may include
bleeding, pulmonary embolism, pneumothorax,
pericardial processes, airway issues, myocardial
ischemia, or infection/sepsis (LOE C).
Class IIb
5.1.4. Cardiology consultation may be useful for those
patients (LOE C) who:
5.1.4.1. Develop recurrent or refractory POAF.
5.1.4.2. Develop a hemodynamically unstable condi-
tion.
5.1.4.3. Are at high risk for stroke based on
CHA2DS2-VASc score and will likely
require longer-term anticoagulation.
5.1.4.4. Require a second-line antiarrhythmic medi-
cation for stabilization.
5.1.4.5. Also develop acute kidney injury.
Reasoning
For all patients with new-onset POAF after thoracic sur-
gery, consideration should be given to triggering causes.
Although inflammation provoked by surgical procedures, pa-
tient risk factors for AF, and mechanical proximity of
thoracic surgery procedures to cardiac structures are often
sufficient to explain the occurrence of POAF, other triggers
may need to be identified in patients with recurring, symp-
tomatic, or refractoryAF. These include bleeding, pulmonary
embolism, pneumothorax, pericardial processes, airway is-
sues, myocardial ischemia, or infection/sepsis. Minimiza-
tion, weaning or discontinuation of catecholaminergic
inotropic agents, if possible, optimization of fluid status,
and correction of any electrolyte/metabolic disturbances
may also facilitate restoration and maintenance of sinus
rhythm.
As a general rule, although much, if not most, POAF is
transient and largely limited to the postoperative period
(2-6 weeks), consultation with a cardiologist or cardiacdiovascular Surgery c Volume 148, Number 3 e169
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FIGURE 2. Management algorithm for postoperative atrial fibrillation (POAF). AF, Atrial fibrillation;MI, myocardial infarction; HF, heart failure;WPW,
Wolff-Parkinson-White syndrome; DC, direct current; i.v./IV, intravenous; HR, heart rate; LV, left ventricular; COPD, chronic obstructive pulmonary dis-
ease; LA/LAA, left atrial/left atrial appendage; TEE, transesophageal echocardiography.
Clinical Guidelines Frendl et alelectrophysiologist may be useful, especially for patients
with recurrent or refractory POAF. This is usually for 3
issues: management of rate control during AF; consider-
ation of whether, when, and how to restore sinus rhythm;
and consideration of anticoagulation. The first issue is
usually not difficult to accomplish, and standard prophy-
lactic use of diltiazem or b blockers usually ensures
that should POAF occur, ventricular rate control may be
as simple as maintaining this therapy. However, tachy-
brady syndrome may complicate efforts at rate control
that may require alternative medical options, rhythm con-
trol strategies, or antibradycardic pacing. The second
issue may be more complex, but decisions about if,
when, and how to restore sinus rhythm often benefits
from direct, nuanced cardiology and/or cardiac electro-
physiology involvement. Such consultation can be useful
in the selection and management of antiarrhythmic med-
ications or in determining a need for permanent pacing.
The third issue is probably the most important and a chal-
lenge particularly for patients at high risk for bleeding.
Cardiologists may assist with management of patients at
high risk for stroke needing longer-term anticoagulation,
unstable patients, or patients with acute kidney injury,
which can worsen outcomes, including stroke, and limit
antiarrhythmic and anticoagulant choices. Close interac-
tion between the surgical team and the cardiology team
should provide excellent, well-considered anticoagulation
decisions. In the end, the patient and thoracic surgical
team will be well served by a close consultative relation-
ship with the cardiologist.e170 The Journal of Thoracic and Cardiovascular SurRecommendations
5.2. Recommendations for the management of the he-
modynamically unstable patient with new-onset
POAF (Figure 3)gerss I
5.2.1. Emergency R-wave synchronized direct current
(DC) electrical cardioversion is recommended
for hemodynamically unstable patients and for
patients with evidence of acute myocardial
ischemia or infarction. Signs of hemodynamic
instability include severe symptomatic hypoten-
sion, shock, or pulmonary edema2-4,38 (LOE C).
5.2.1.1. For unstable patients with new-onset POAF
of less than 48-hours duration, emergency
DC cardioversion is indicated and is accept-
able before initiation of anticoagulation2,3
(LOE C).
5.2.1.2. For unstable patients who undergo cardio-
version more than 48 hours after the onset
of AF, and who do not have an excessive
bleeding risk or other contraindication, anti-
coagulation should be initiated as soon as
possible and continued for at least 4 weeks2,3
(LOE C).
ss IIa
5.2.2. If initial DC cardioversion is unsuccessful or he-
modynamically unstable AF recurs, the following
steps can be useful:y c September 2014
FIGURE 3. Management of the hemodynamically unstable patient with new onset postoperative atrial fibrillation (POAF). AF, Atrial fibrillation; MI,
myocardial infarction; HF, heart failure; DC, direct current; i.v., intravenous; TEE, transesophageal echocardiography.
Frendl et al Clinical Guidelines5.2.2.1. Initiate rate and possible rhythm control
therapy with intravenous esmolol, diltiazem,
digoxin, or amiodarone while preparing for
repeat DC cardioversion (LOE C).
5.2.2.2. Repeat DC cardioversion (more likely to be
successful after initiating a rhythm control
agent) (LOE C).ClReasoning
Some patients with new-onset AF are hemodynamically
unstable, defined as AF associated with symptomatic severe
hypotension, evidence of acute myocardial ischemia or
infarction, or pulmonary edema/heart failure. For such
patients, immediate electrical DC cardioversion is recom-
mended.2,3 Electrical cardioversion should be performed
under deep conscious sedation with R-wave synchronized
shocks. Cardioversion can be performed with biphasic or
monophasic waveforms. However, biphasic waveform
shocks are preferred over monophasic waveforms, as the
latter can require higher defibrillation energies for
success. Anterior-posterior electrode patch positioning
(eg, R parasternal to L posterior or midlow sternal to poste-
rior) may produce a more successful defibrillation
vector for cardioversion of AF than anterior only (eg, R par-
asternal to anterior or anterolateral apex) positions. If DC
cardioversion using 1 defibrillator patch location fails, the
alternate patch position should be used.
If AF duration in the unstable patient is less than 48 hours,
cardioversion can be performed before initiation of anticoa-
gulation.2,3,43 However, for patients with AF of more than 48
hours duration who become hemodynamically unstable,The Journal of Thoracic and Carthere is a higher risk of left atrial or atrial appendage
thrombus that could dislodge at the time of or in the days
following cardioversion in the absence of anticoagulation.
Thus, it is recommended that for these patients, in the
absence of contraindications (such as excessive bleeding
risk or known heparin sensitivity), heparin be administered
concurrently with the cardioversion, and used during
transition to an oral anticoagulant. The oral anticoagulant
should be provided for at least 4 weeks after cardioversion,
as for patients undergoing elective cardioversion2,3,43
If the initial cardioversion is unsuccessful or hemody-
namically unstable AF recurs, repeat cardioversion can be
attempted. To facilitate this, and while preparing for repeat
cardioversion, attempts at pharmacologic rate or rhythm
control may be considered with such drugs as intravenous
amiodarone, esmolol, diltiazem, or digoxin.When hypoten-
sion is a problem, intravenous digoxin may be considered.
However, should pharmacologic management fail, repeat
electrical cardioversion is recommended.
Recommendations
5.3. Recommendations for the management of the he-
modynamically stable patient with new-onset AF
(Figures 4 and 5)
Primary treatment goal is rate control with rhythm
control as a secondary option.diass IIa
5.3.1. It is reasonable to manage stable, well-tolerated
new-onset POAF with a rate control strat-
egy2,104,125-127 (LOE C).ovascular Surgery c Volume 148, Number 3 e171
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DC cardioversion can be useful for patients with
hemodynamically stable new-onset POAF who
have recurrent or refractory POAF, continued
symptoms, intolerance to rate control medica-
tions, or ventricular rates that cannot be
adequately controlled2,126,127 (LOE C).
5.3.3. A rhythm control approach with pharmacologic or
DC cardioversion is reasonable for patients with
new-onset POAF nearing 48 hours in duration,
who are at high risk for bleeding, in order to
avoid anticoagulation that would be otherwise
indicated for AF persisting longer than 48 hours
(LOE C).
Reasoning
Similar to AF occurring after cardiac surgery, new-onset
POAF after thoracic surgery is often self-limited with
patients returning to sinus rhythm within 4 to 6 weeks after
surgery regardless of a rate or rhythm control strategy. An
observational study of 30 patients with new-onset AF after
lung resection and no history of heart rhythm disease
reported that sinus rhythm was restored within the first
24 hours in 70% of patients treated with diltiazem, and in
67% of patients treated with amiodarone; after 48 hours,
80% in both groups were in sinus rhythm.125 AF recurred
in 11 (37%), but 10 converted after intravenous treatment.
In a retrospective review of 41 patients who developed
POAF after lung resection, 98% of AF disappeared within
a day of discharge and 85.4% required pharmacologic man-
agement, but none required electrical cardioversion.104 Sinus
rhythm was restored after loading with digoxin in 80%,
11.5% after amiodarone, and 8.5% with both. All patients
except 1 were discharged in sinus rhythm. In another study
of aortic surgery in 211 patients, 22 developed POAF; 16
spontaneously converted to sinus rhythm, 2 converted chem-
ically and 1 electrically, and 3 continued in AF at discharge,
but all were in sinus rhythm documented with an ECG a
mean of 14 months after discharge.128 Thus, most patients
with new POAF after thoracic surgery can be expected to re-
turn to sinus rhythm regardless of a rate or rhythm control
strategy.
Rate versus rhythm control strategies have been studied in
randomized trials for non-POAF.129-133 The largest of these,
the Atrial Fibrillation Follow-Up Investigation of Rhythm
Management (AFFIRM) study,129 was powered to detect a
difference in overall mortality, but showed no difference be-
tween a strategy of rhythm versus rate control in the primary
end point of all-cause mortality, with a slight trend toward
better survival in the rate control arm. Secondary analyses
demonstrated no differences in quality of life,134 although
other subanalyses demonstrated better mortality in patients
in sinus rhythm or on warfarin,135 and a functional status
substudy demonstrated better NYHA functional class ine172 The Journal of Thoracic and Cardiovascular Surthe rhythm control arm and longer 6-minute walk test dis-
tances in patients in sinus rhythm.136
However, there are no randomized trials studying rate
versus rhythm control strategies for POAF after thoracic
surgery, and there have been only small, randomized, pilot
trials performed after cardiac surgery. In a randomized pilot
study by Lee and colleagues126 of 50 patients with POAF
after cardiac surgery, 27 were randomized to antiarrhythmic
drug therapy  electrical cardioversion and 23 to a rate
control approach. The end points were length of stay and
incidence of recurrent AF. There was no significant differ-
ence in time to conversion to sinus rhythm. With multivari-
able Cox analyses, adjusting for other covariates, there was
a trend toward a reduction in time from treatment to sinus
rhythm in the antiarrhythmic arm (P ¼ .08), as well as a
shorter length of stay (P ¼ .05). At termination, 91%
were in sinus rhythm in the rate control arm and 96%
were in sinus rhythm in the antiarrhythmic arm. Most
were in sinus rhythm after 2 months. In a randomized pilot
study by Soucier and colleagues127 of stable patients with
new AF after cardiac surgery, 42 patients were randomized
to propafenone 600 mg (n¼ 20) versus ibutilide 1 mg intra-
venously up to 2 doses (n¼ 10) versus rate control (n¼ 12).
At 24 hours, 0%, 65%, and 34% of patients in the ibutilide
(P ¼ .01), propafenone (P> .05), and rate control arms
remained in AF. Ibutilide decreased AF duration, but recur-
rence rates were 90%, 41%, and 58% in the 3 arms (P>
.05). The 3 patients who did not convert all received prop-
afenone. There were no differences in length of stay or
rhythm at discharge. These 2 small prospective randomized
pilot studies thus showed few differences between rate and
rhythm control strategies.
The absence of significant differences in the small rate
versus rhythm control studies of AF after cardiac surgery
justifies the use of either rate or rhythm control strategies
in patients with new-onset POAF who are hemodynamical-
ly stable. However, the high rate of spontaneous conversion
to sinus rhythm in the first 24 hours after onset of POAF
makes it reasonable to opt for an initial rate control
approach in stable patients, especially over the first 24 hours.
Because anticoagulation is generally recommended in pa-
tients with AF lasting longer than 48 hours, the higher risks
of postoperative bleeding with anticoagulation can also
justify a rhythm control approach in patients with new
postoperative AF that persists longer than 24 hours despite
a rate control approach. A rhythm control approach with
pharmacologic or electrical cardioversion may also be
reasonable in patients whose ventricular rates cannot be
adequately controlled, or in patients who either do not
tolerate AV nodal blockers to control ventricular rate or
who remain symptomatic or hemodynamically compro-
mised despite control of the ventricular rate.
For the patient with stable hemodynamics and minimal
symptoms, a trial of rate control for the first 24 hours isgery c September 2014
FIGURE 4. Management of the hemodynamically stable patient with new onset postoperative atrial fibrillation (POAF) of less than 48 hours duration.
WPW, Wolff-Parkinson-White syndrome;HR, heart rate; i.v., intravenous; HF, heart failure; LV, left ventricular; COPD, chronic obstructive pulmonary dis-
ease; AF, atrial fibrillation; DC, direct current; TEE, transesophageal echocardiography.
Frendl et al Clinical Guidelinesgenerally recommended, as a high proportion will convert
to sinus rhythmwithin 24 hours using rate control or rhythm
control agents. Inotropes should be stopped or reduced, if
clinically acceptable, fluid balance optimized, and normal
electrolyte balance maintained. Rate control may be
achieved with intravenous esmolol or metoprolol, intrave-
nous diltiazem, intravenous verapamil (although this carries
more risk for hypotension than diltiazem), digoxin (espe-
cially if there is hypotension or heart failure), or intravenous
amiodarone. If AF persists, DC cardioversion may beThe Journal of Thoracic and Carconsidered within 48 hours of onset; anticoagulation is
indicated for AF persisting for more than 48 hours. Alterna-
tively, if the AF is well tolerated, the patient could be started
on anticoagulation and rate control with plans for elective
cardioversion in 4 to 6 weeks. If AF is recurrent after cardio-
version, antiarrhythmic therapy with repeat DC cardiover-
sion can be continued with maintenance oral therapy for
4 to 6 weeks, or a rate control approach can be adopted
with anticoagulation and plans for elective cardioversion
if AF persists after 4 to 6 weeks (see Figures 2, 4, and 5).diovascular Surgery c Volume 148, Number 3 e173
FIGURE 5. Management of the hemodynamically stable patient with new onset postoperative atrial fibrillation (POAF) of more than 48 hours duration.
WPW, Wolff-Parkinson-White syndrome;HR, heart rate; i.v., intravenous; HF, heart failure; LV, left ventricular; COPD, chronic obstructive pulmonary dis-
ease; TEE, transesophageal echocardiography; LA/LAA, left atrial/left atrial appendage; DC, direct current; AF, atrial fibrillation.
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5.4. Medical management of patients with new-onset
POAF (Figures 4 and 5)
5.4.1. Rate control recommendationsClass
Class
e174I
5.4.1.1. Intravenous administration of b-blockers
(eg, esmolol or metoprolol) or non–dihy-
dropyridine calcium channel blockers
(diltiazem or verapamil) is recommended
to achieve rate control (heart rate 110The Journal of Thoracic and Cardiovascular Surgerybpm) for patients who develop POAF
with rapid ventricular response2,44,125
(LOE B).
5.4.1.1.1. Caution should be used with patients
with hypotension, LV dysfunction, or
heart failure2,38,44,125 (LOE B).
IIa
5.4.1.2. Combination use of AV nodal blocking
agents, such as b-blockers (eg, esmolol
or metoprolol), non–dihydropyridine cal-
cium channel antagonists (eg, diltiazemc September 2014
Clas
Clas
Frendl et al Clinical Guidelinesor verapamil), or digoxin, can be useful
to control heart rates when a single
agent fails to control rates of POAF.
The choice should be individualized and
doses modified to avoid bradycardia2,38
(LOE B).
5.4.1.3. For patients with hypotension, heart failure,
or LV dysfunction, or when other measures
are unsuccessful or contraindicated, intrave-
nous amiodarone can be useful for control
of heart rate. Amiodarone could result in
conversion to sinus rhythm, and if it is
initiated after 48 hours of AF, both tran-
sesophageal echocardiography (TEE) when
possible, to rule out left atrial (LA)/LA
appendage (LAA) thrombus, and full
anticoagulation should be consid-
ered3,83,104,125,137 (LOE B).
s IIb
5.4.1.4. For patients with heart failure, LV dysfunc-
tion, or hypotension, intravenous digoxin
may be considered for rate control of
POAF38,99,104 (LOE B).
s III
5.4.1.5. For patients with ventricular preexcitation
(ie, Wolff-Parkinson-White syndrome)
and POAF, use of AV nodal blocking
agents, such as b-blockers (eg, esmolol
or metoprolol), intravenous amiodarone,
non–dihydropyridine calcium channel
antagonists (eg, diltiazem or verapamil),
or digoxin, should be avoided2,38
(LOE C).Reasoning
Achieving control of ventricular rates in AF is a first-line
approach to patients with POAF after thoracic surgery.
This may be achieved using intravenous or oral AV nodal
blocking agents, but intravenous b-blockers or non–dihy-
dropyridine calcium channel blockers (eg, diltiazem,
verapamil) can often achieve more rapid rate control than
oral agents. Choice of agents is usually based on comorbid-
ities. b-Blockers have often been first-line therapy for ven-
tricular rate control after cardiac surgery, and may be
preferred over calcium channel blockers in patients with
coronary disease. Calcium channel blockers are preferred
in patients with bronchospasm limiting consideration of
b-blockers, but should be avoided in patients with heart
failure or severe LV dysfunction. Diltiazem is often as
effective as b-blockers with less hypotension, can be
titrated as a continuous infusion, and has a greater margin
of safety than verapamil, which may be limited by
hypotension.The Journal of Thoracic and CarThe use of digoxin is generally less effective in the acute
postoperative high catecholaminergic state, and it has a
slower onset of action. But in the face of hypotension,
digoxin may be the treatment of choice. b-Blockers and
calcium channel blockers have been shown to be more
effective at controlling ventricular rates with shorter times
to effect than digoxin. Tisdale and colleagues99 compared
intravenous diltiazem (n ¼ 20) versus digoxin (n ¼ 20).
The end points included ventricular rate control, defined
as a 20% or greater decrease in pretreatment ventricular
rate and postoperative length of stay. Intravenous diltiazem
achieved rate control within a mean of 10 minutes
compared with 352 minutes with digoxin (P< .0001). At
2 and 6 hours, successful rate control was higher in the dil-
tiazem group, but by 24 hours there was no difference, as
conversion to sinus rhythm occurred in 55% on diltiazem
and 65% on digoxin. There was no difference in postoper-
ative length of stay. However, digoxin may be particularly
useful in patients with heart failure, LV dysfunction, or
hypotension, or in combination with other agents. The
addition of digoxin might also facilitate a lower dose of
b-blockers or calcium channel blockers in patients with hy-
potension. Combination use of b-blockers, calcium channel
blockers, or digoxin can be attempted in patients with rapid
rates refractory to monotherapy, but caution should be exer-
cised with dosage modification to avoid hypotension and
bradycardia, including pauses on termination of AF.
It should be noted that in the presence of ventricular
preexcitation (Wolff-Parkinson-White syndrome), AV
nodal blocking agents, such as calcium channel blockers,
b-blockers, digoxin, and intravenous amiodarone may
potentiate rapid conduction through the accessory atrioven-
tricular pathway due to removal of concealed conduction
from the AV node. Digoxin may also shorten the AV node
effective refractory period within the accessory pathway.
For these patients, AV nodal blocking agents should be
avoided, and antiarrhythmic medication (intravenous ibuti-
lide, amiodarone, or procainamide) considered.
Amiodarone has also been used for ventricular rate
control. However, as its antiarrhythmic properties could
lead to conversion of AF to sinus rhythm, caution should
be exercised if amiodarone is initiated after 24 to 48 hours
after the onset of AF, as there is a possibility that the AF
could convert to sinus rhythm with the attendant risk of
thromboembolism. In these circumstances, TEE should be
considered to exclude left atrial or left atrial appendage
thrombi before initiation of amiodarone.
Parameters for optimal control of ventricular rates dur-
ing AF remain controversial. The RACE II study44 evalu-
ated a lenient (resting heart rate<110 bpm) versus strict
(resting heart rate<80 bpm) rate control strategy in 614
patients with permanent AF. There was no difference in
cardiovascular death, hospitalization for heart failure,
stroke, systemic embolism, bleeding, and life-threateningdiovascular Surgery c Volume 148, Number 3 e175
5.4
Class
5.4
Clinical Guidelines Frendl et alarrhythmic events. The mean ventricular rate in the lenient
control group was 85 bpm and 76 bpm in the strict control
group at the end of the follow-up period. Although this
population is different from patients with new-onset
POAF, more lenient rate control (to heart rate 110
bpm) may be preferable to strict rate control in the postop-
erative setting when patients are prone to hemodynamic
instability or hypotension. The normal metabolic response
to surgery is associated with an increase in catechol-
amines, often manifested in sinus tachycardia in the early
perioperative period and reflected in higher ventricular
rates in AF.
There are nodata to suggest efficacy for addingmagnesium
or potassium to facilitate conversion to sinus rhythm or to
improve rate control after thoracic surgery. However, it seems
reasonable to recommend maintaining normal levels.5.4
Recommendations
5.4.2. Recommendations for the use of antiarrhythmic
drugs (Figure 6, A and B)Cla
Cl
e17ss IIa
5.4.2.1. Restoration of sinus rhythm with pharmaco-
logic cardioversion is reasonable in patients
with symptomatic, hemodynamically stable
POAF138-140 (LOE C).
5.4.2.1.1. Intravenous amiodarone can be useful
for pharmacologic cardioversion of
POAF15,95,104,125,137 (LOE B).
5.4.2.2. It is reasonable to administer antiarrhythmic
medications in an attempt to maintain sinus
rhythm for patients with recurrent or refractory
POAF2,141 (LOE B).
5.4.2.2.1. Amiodarone, sotalol, flecainide, propafe-
none, or dofetilide can be useful to maintain
sinus rhythm in patients with POAF, de-
pending on underlying heart disease, renal
status and other comorbidities (see Table
7)2 (LOE B).ass
5.4
5.4
6IIb
.2.3. Flecainide or propafenonemay be considered for
pharmacologic cardioversion of POAF and
maintenance of sinus rhythm if the patient
has had no previous history of myocardial
infarction, coronary artery disease, impaired
LV function, significant LV hypertrophy, or
valvular heart disease that is considered
moderate or greater. These agents may need to
be combined with an AV nodal blocking
agent95,142-146 (LOE C).
.2.4. Intravenous ibutilide or procainamide may be
considered for pharmacologic conversion of
POAF for patients with structural heart diseaseThe Journal of Thoracic and Cardiovascular Surgeryand new-onset POAF, but no hypotension or
manifestations of congestive heart failure.
Serum electrolytes and QTc interval must be
within a normal range and patients must be
closely monitored during and for at least 6 hours
after the infusion if either ibutilide or procaina-
mide77,143,147-149 (LOE B).
.2.5. Intravenous ibutilide or procainamide may be
considered for patients with POAF and an
accessory pathway2,38 (LOE B).
III
.2.6. Flecainide and propafenone should not be used
to treat POAF in patients with a history of a pre-
vious myocardial infarction, coronary artery
disease, and/or severe structural heart disease,
including severe left ventricular hypertrophy,
or significantly reduced left ventricular ejection
fraction2,60 (LOE B).
.2.7. Dronedarone should not be used for treatment
of POAF in patients with heart failure2,72
(LOE B).Reasoning
For patients with symptomatic but hemodynamically
stable AF after thoracic surgery, consideration should
be given to restoring sinus rhythm with pharmacologic
cardioversion.138-140 Although 1 study demonstrated a
cardioversion rate of 86% with intravenous amiodarone
in patients undergoing pulmonary resection for lung
carcinoma,95,125 a meta-analysis that included both medi-
cal and POAF suggested a slightly lower rate of conver-
sion of 76%.15,95,104,125,137,142 The class IC
antiarrhythmic drugs (flecainide, propafenone) may also
be considered to restore and maintain sinus rhythm.
Reisinger and colleagues143 compared the efficacy and
safety of intravenous flecainide versus intravenous ibuti-
lide in patients with recent-onset AF and showed that
the rate of cardioversion was similar (56% vs 50%, P>
.05). However, it should be appreciated that the intrave-
nous form of flecainide is not available in the United
States and an oral loading dose of flecainide (and propafe-
none) would be required to restore sinus rhythm.95,142-146
It is usually customary to combine flecainide and
propafenone with AV nodal blocking agents to prevent
1:1 atrial flutter and rapid ventricular conduction.
Ibutilide is another antiarrhythmic drug that has
moderate efficacy at restoring sinus rhythm.143 However,
it is only available in an intravenous form and it necessi-
tates close monitoring of serum electrolytes and QTc. Pa-
tients must be monitored during and after intravenous
ibutilide for at least 6 hours.2,147
For patients with recurrent symptomatic POAF, it is
reasonable to not only restore sinus rhythm but also
consider maintaining sinus rhythm with antiarrhythmicc September 2014
FIGURE 6. A, Antiarrhythmic drugs recommended for pharmacologic cardioversion of postoperative atrial fibrillation (POAF). B, Antiarrhythmic drugs
recommended for maintenance of sinus rhythm after cardioversion of POAF.MI, Myocardial infarction; CAD, coronary artery disease; LV, left ventricular;
AV, atrioventricular; CHF, congestive heart failure; HF, heart failure.
Frendl et al Clinical Guidelinesdrugs. Although many membrane active drugs (amio-
darone, sotalol, flecainide, propafenone, dofetilide, or
dronedarone) have been shown to prevent recurrences
of AF in both POAF and in the nonoperative setting
with variable efficacy, the choice of antiarrhythmic
drug is very much governed by associated comordibi-
ties, such as structural heart disease and impaired renalThe Journal of Thoracic and Carfunction. Overall, the selection of antiarrhythmic drugs
to maintain sinus rhythm after thoracic surgery is
similar to that outlined in the recently published AF
guidelines for the management of nonoperative AF.2,3
A review of antiarrhythmic drugs, their side effects,
and interactions are outlined in section 3 and in
Tables 6 and 7.diovascular Surgery c Volume 148, Number 3 e177
Clinical Guidelines Frendl et alRecommendations
5.5. Nonpharmacologic management of POAF
5.5.1. Recommendations for DC cardioversion for
stable patients with POAF
Class
Class
Cla
e178I
5.5.1.1. DC cardioversion is recommended for symp-
tomatic or relatively hemodynamically
compromised patients with POAF if they
do not respond promptly to pharmacologic
attempts to control rapid ventricular
rates2,3,43 (LOE C).
5.5.1.2. DC cardioversion is recommended for patients
without hemodynamic instability when symp-
toms of AF are unacceptable to the patient or
when rapid ventricular rates do not respond
to pharmacologic measures2 (LOE C).
IIa
5.5.1.3. DC cardioversion can be a reasonable
alternative to pharmacologic cardiover-
sion138-140 (LOE C).
5.5.1.4. Pretreatment with an antiarrhythmic drug can
be useful to enhance the success ofDCcardio-
version (as described in section 5.2.2.1.1) and
to prevent recurrent AF2 (LOE B).
5.5.1.5. Caution is advised for patients with preopera-
tive or unknown sinus node dysfunction or
with patients receiving significant doses of
rate controlling medications, as significant
pauses can occur after DC cardioversion. For
those patients, external pacingmaybe required
and should be readily available (LOE C).
5.5.1.6. It is reasonable to repeat DC cardiover-
sion, after administration of an antiar-
rhythmic medication, for patients who
relapse to AF after successful cardiover-
sion2,43 (LOE C).
5.5.1.7. Patient and physician preference are
reasonable considerations for selecting DC
cardioversion2 (LOE C).5.6. Recommendations for prevention of thromboembo-
lism for patients with stable atrial fibrillation/flutter
undergoing DC cardioversionss I
5.6.1. For stable patients with POAF of 48 hours dura-
tion or longer, anticoagulation (with warfarin
for internationalized normalized ratio [INR] 2.0-
3.0, an NOAC or low molecular weight heparin
[LMWH]) is recommended for at least 3 weeks
before and 4 weeks after cardioversion, regardless
of the method (electrical or pharmacologic) used
to restore sinus rhythm2 (LOE B).The Journal of Thoracic and Cardiovascular SurClass IIa
5.6.2. During the first 48 hours after the onset of POAF,
the need for anticoagulation before and after DC
cardioversion may be based on the patient’s risk
of thromboembolism (CHA2DS2-VASc score;
Figures 9 and 10) balanced by the risk of
postoperative bleeding2 (LOE C).
5.6.3. For POAF lasting longer than 48 hours, as an
alternative to 3 weeks of therapeutic anticoagu-
lation before cardioversion of POAF, it is
reasonable to perform TEE in search of
thrombus in the LA or LA appendage, preferably
with full anticoagulation at the time of TEE in
anticipation of DC cardioversion after the
TEE150-151 (LOE B).
5.6.3.1. For patients with no identifiable thrombus,
DC cardioversion is reasonable imm-
ediately after the TEE examination if thera-
peutic anticoagulation is achieved.
Anticoagulation should continue for at least
4 additional weeks although the benefits
must be weighed against the risk of
bleeding2,151 (LOE C).
5.6.4. For POAF lasting longer than 48 hours in patients
who are not candidates for TEE (eg, after esoph-
ageal surgery), an initial rate control strategy
combined with therapeutic anticoagulation using
warfarin (aiming for INR 2.0-3.0), a direct
thrombin inhibitor (eg, dabigatran), factor Xa in-
hibitor (eg, rivaroxaban, apixaban), or LMWH is
recommended for at least 3 weeks before and 4
weeks after cardioversion (LOE C).
5.6.5. Anticoagulation recommendations for cardiover-
sion of atrial flutter are similar to those for atrial
fibrillation2 (LOE C).
Class III
5.6.6. For patients with an identified thrombus, cardio-
version should not be performed until a longer
period of anticoagulation is achieved (usually at
least 3 weeks) and in accordance with established
AF guidelines2,150,151 (LOE B).
Reasoning
Electrical DC cardioversion is recommended for new-
onset POAF that is associated with unstable hemodynamics.
DC cardioversion should be performed under deep
conscious sedation with R-wave synchronized shocks.
Biphasic waveform shocks are preferred over monophasic
waveforms, which can require higher defibrillation energies
for success.
Commonly, rate control is attempted for at least the first
24 hours, because up to 80% of patients may spontaneouslygery c September 2014
Cl
Frendl et al Clinical Guidelinesconvert with rate control alone (see rate control agents in
Table 6). For patients with persistent AF and significant
symptoms despite attempts to control ventricular response,
pharmacologic or electrical cardioversion can be consid-
ered. When AF nears 48 hours in duration, such pharmaco-
logic or electrical cardioversion may be reasonable,
particularly in patients who are at high risk for bleeding,
to avoid anticoagulation that would otherwise be indicated
for AF persisting longer than 48 hours (see section 5.3.1).
Pretreatment with an antiarrhythmic drug (see Table 7)
can be useful to enhance the success of electrical cardiover-
sion and prevent recurrent AF. However, this requires some
caution if the preoperative or current status of sinus node
function is unknown. If sinus node dysfunction is present,
because most antiarrhythmic drugs suppress sinus node
function, successful cardioversion can be associated with
initial prolonged asystole and/or prolonged hypotension.
In such patients, readiness for external pacing should be
anticipated. If the status of sinus node function is unknown,
proceeding to electrical cardioversion without administra-
tion of a precardioversion antiarrhythmic drug is
reasonable.
For recurrent AF after initial conversion to sinus rhythm,
cardioversion may be considered, often after initiation of an
antiarrhythmic drug to prevent further recurrences. For
recurrent or refractory AF, evaluation for potential trig-
gering causes should be investigated. These include
bleeding, pulmonary embolism, pneumothorax, pericardial
processes, airway issues, myocardial ischemia, infection,
sepsis, or use of catecholaminergic inotropes. Should AF
manifest as frequent paroxysms with intervening episodes
of sinus rhythm, electrical cardioversion is not recommen-
ded, unless AF becomes persistent, because AF is likely
to recur after cardioversion. In these situations, an antiar-
rhythmic drug may be beneficial.
For AF longer than 48 hours in duration, anticoagulation
with warfarin (INR 2.0-3.0), a direct thrombin inhibitor (eg,
dabigatran), factor Xa inhibitor (eg, rivaroxaban, apixaban),
or LMWH is recommended for at least 3 weeks before and 4
weeks after cardioversion, as in other patients with AF. As
an alternative to anticoagulation before cardioversion of
AF, TEE may be performed in search of thrombus in the
LA or LAA. It is preferable to perform the TEE on full
anticoagulation with heparin or therapeutic levels of oral
anticoagulants, and then to perform electrical or pharmaco-
logic cardioversion immediately afterwards on therapeutic
anticoagulation. This is preferred over performing a TEE
while off anticoagulation or on subtherapeutic anticoagula-
tion, because a thrombus may form between the time of
TEE and full anticoagulation. In patients with no identifi-
able thrombus, cardioversion is reasonable immediately
after TEE on therapeutic anticoagulation, with anticoagula-
tion continued for at least 4 weeks afterwards, as for pa-
tients undergoing elective cardioversion. For patients withThe Journal of Thoracic and Caran identified thrombus, cardioversion should be deferred
until a longer period of anticoagulation is achieved and in
accordance with established AF guidelines. The TEE-
guided cardioversion approach is supported by results of
the ACUTE trial,151 which enrolled 1222 patients with
AF of greater than 2 days duration and randomized them
to TEE-guided cardioversion versus warfarin anticoagula-
tion for at least 3 weeks before cardioversion. There was
no difference between the groups in the rate of embolic
events, but the rate of hemorrhagic events was lower in
the TEE group. Exclusion of left atrial thrombus by TEE
does not preclude thromboembolism in the absence of ther-
apeutic anticoagulation. Black and colleagues152 reported
17 patients with nonvalvular AF who had embolic events
2 hours to 7 days after cardioversion despite a TEE showing
no LA thrombus. None of the patients were on therapeutic
anticoagulation at the time of the embolism. Thus, the
TEE-guided cardioversion strategy should be coupled
with therapeutic anticoagulation at the time of and after car-
dioversion for patients in whom the duration of AF is
greater than 48 hours.
It is recognized that in the thoracic surgery population,
some patients will not be candidates for TEE because of
esophageal procedures, including esophagectomy (or
those with esophageal pathology). In these patients, if
AF duration is greater than 48 hours, an initial rate control
approach is reasonable with therapeutic anticoagulation,
using warfarin (INR 2.0-3.0), a direct thrombin inhibitor
(eg, dabigatran), factor Xa inhibitor (eg, rivaroxaban,
apixaban), or LMWH, recommended for at least 3 weeks
before and 4 weeks after cardioversion. Cardiac computed
tomography has been used to assess for LAA thrombus,
predominantly before AF catheter ablation. A recent
meta-analysis153 reported accuracy comparable with
TEE, especially when delayed images were acquired,
with a sensitivity and specificity of 96% and 92%
compared with TEE, a positive predictive value of 41%,
and a negative predictive value of 99%. As clinical out-
comes studies are needed to assess its clinical usefulness
for cardioversion, in the case of patients with esophageal
surgical procedures precluding TEE, the rate control strat-
egy with deferred cardioversion until at least 3 weeks of
therapeutic anticoagulation is achieved seems reasonable.
For selected patients, cardiac computed tomography may
be of some value.
Recommendation
5.7. Recommendation for electrophysiology catheter
ablationdiass III
5.7.1. Catheter or surgical ablation of AF is not recom-
mended for management of patients with postop-
erative AF after thoracic surgery (LOE C).ovascular Surgery c Volume 148, Number 3 e179
Clinical Guidelines Frendl et alReasoning
Catheter ablation of AF is a well-established and
commonly used therapeutic option for managing patients
with symptomatic AF.2,3 At the present time, catheter
ablation of AF plays no role in the management of
patients who develop AF in the early postoperative
setting. This recommendation is based on several
important considerations. First, all patients who undergo
catheter ablation of AF must be anticoagulated for a
minimum of 2 months after ablation. Patients who cannot
be anticoagulated continuously for 2 months are not
considered to be candidates for ablation. Second, catheter
ablation of AF is a complex and lengthy procedure (3-6
hours) that is most commonly performed under general
anesthesia. Third, it is common for AF to recur in the 2-
to 3-month postablation healing phase. This reflects the
presence of considerable inflammation and lesion matura-
tion that occurs after ablation. The presence of these healing
phase arrhythmias means that AF ablation is an inappro-
priate strategy for the control of acute, symptomatic AF,
such as occurs in the postoperative setting. Fourth, the effi-
cacy of catheter ablation is modest. In optimal candidates
for the procedure with paroxysmal AF who are otherwise
healthy, the single procedure success rate at 12 months is
60% to 80%. Late recurrences after 12 months of follow-
up are common. Fifth, AF ablation is associated with a sig-
nificant risk of complications. For more information
regarding the technique, risks, indications, and outcomes
of AF ablation, please refer to the 2012 Heart Rhythm So-
ciety/European Society of Cardiology/European Cardiac
Arrhythmia Society Expert Consensus Statement on Cath-
eter and Surgical Ablation of Atrial Fibrillation.154
Recommendations
5.8. Surgical and interventional treatment options
5.8.1. Recommendations for preexisting AFClass
e180I
5.8.1.1. Preexisting AF should be managed accord-
ing to existing guidelines for non–postopera-
tive AF (see section 6).Cla
ClaReasoning
Preexisting AF should be treated according to the exist-
ing guidelines for nonsurgical AF.2,3 In the rare situation
where a patient cannot be treated with anticoagulation,
consideration could be given to intraoperative LAA
resection or ligation. This could only be done if the
patient is undergoing a left thoracotomy procedure.
Regarding PVI procedures, a complete bilateral procedure
can only be performed in the rare situation when bilateral
thoracotomies are performed or if a clam-shell incision is
used.
For new-onset AF after thoracic surgery, an intraopera-
tive procedure is not indicated based solely on a predictionThe Journal of Thoracic and Cardiovascular Surmodel for patients likely to develop POAF. Procedures such
as PVI and/or LAA resection or ligation are not routinely
practiced for the prevention of POAF in cardiac surgery,
where the exposure allows such procedures to be performed
easily.
It is well known that the most POAF is self-limiting in
4 to 6 weeks. For persistent AF beyond that time or
POAF requiring long-term anticoagulation, patients should
be referred to a cardiologist/cardiac electrophysiologist for
future management according to general AF guidelines. If
such patients are intolerant of antiarrhythmic medications,
a catheter-based ablation procedure may be offered accord-
ing to the existing guidelines for AF ablation. A surgical
ablation procedure can be offered in the rare instance of a
patient requiring a cardiac surgical procedure. A full PVI
or LA maze and possible right atrial maze procedure may
be performed. In addition, a LAA exclusion procedure
could be also performed. If such patients are intolerant of
long-term anticoagulation, LAA exclusion could be
considered.124,1556. Management of the Patient With Preexisting AF
Patients with preexisting AF represent a high-risk
population for stroke, heart failure, and other POAF-
related complications. Some may have valvular heart dis-
ease. The management of their antiarrhythmic medications
and their perioperative anticoagulation may pose a chal-
lenge (Figure 7).
Recommendations
6.1. Criteria for obtaining cardiology consult for preop-
erative AFClass IIa
6.1.1. Preoperative cardiology consult can be useful
for patients with preoperative AF that is either
newly diagnosed or persistent and symptomatic
(LOE C).
6.2. Perioperative management of anticoagulation for
patients on long-term (warfarin or NOAC) anticoagu-
lation.gerss I
6.2.1. Decisions regarding the duration of interruption
of anticoagulation and/or the need for periopera-
tive heparin bridging should be based on the pa-
tient’s stroke risk profile (based on their
CHA2DS2-VASc score) (LOE C).
ss IIa
6.2.2. For patients who have a high stroke risk (based on
their CHA2DS2-VASc score (Figures 9 and 10),
history of stroke, or presence of a mechanical
heart valve, perioperative bridging with a short-
acting anticoagulant (ie, enoxaparin) is reasonabley c September 2014
FIGURE 7. Algorithm for the management of patients with preoperative atrial fibrillation (AF). Preop, Preoperative; CHF, congestive heart failure; SOB,
shortness of breath; EF, ejection fraction.
Frendl et al Clinical Guidelinesfor patients with estimated glomerular filtration
rate greater than 50% when warfarin anticoagula-
tion is withheld (LOE C).
Class IIb
6.2.3. Short-term withdrawal of anticoagulation without
bridging may be considered for those patients
who are on anticoagulation preoperatively as part
of their treatment for persistent AF but have a
CHA2DS2-VASc score less than 2, have not had
heart failure, have an ejection fraction greater
than 35%, and/or for whom bridging anticoagula-
tionwould be burdensome or otherwise undesirable
(LOE C).
6.3. Postoperative resumption of anticoagulation
Cl
Class IIa
6.3.1. If anticoagulation is interrupted, the duration
should be minimized. It is reasonable to base
decisions about the duration of interruption and
the time of resumption of anticoagulation on the
patient’s stroke risk profile (CHA2DS2-VASc
score) weighed against the risk of postoperative
bleeding (LOE C).6.4. Postoperative follow-up
ass IIb
6.4.1. It is reasonable to consider postoperative follow-
up with a cardiology specialist for patients withThe Journal of Thoracic and Carpreoperatively identified AF who meet 1 or
more of the following criteria:
6.4.1.1. Ejection fraction 45% or less or a diagnosis
of systolic heart failure or cardiomyopathy
6.4.1.2. Discharged on a new rate control and/or
rhythm control agent(s)
6.4.1.3. Dose of a home rhythm control agent(s) was
adjusted while an inpatient
6.4.1.4. Discharged on a new anticoagulant (paren-
teral and/or oral) (LOE C)
Reasoning
In the Rivaroxaban Once Daily Oral direct Factor Xa
Inhibition Compared with Vitamin K Antagonism for Pre-
vention of Stroke and Embolism in Atrial Fibrillation
(ROCKET AF) trial comparing warfarin and rivaroxaban
for the prevention of thromboembolism in nonvalvular
AF, 33% of the 14,236 patients had a temporary interrup-
tion of anticoagulation of greater than or equal to 3 days
(mean duration 5 days). Eighty-one percent of these pa-
tients had persistent AF and more than 99% had a
CHADS2 score greater than or equal to 2 (mean 3.4).
156
Fifty percent of the patients had a history of stroke or tran-
sient ischemic attack and 62% had a history of congestive
heart failure. Forty percent of the temporary interruptions
were for procedures, although only 14% were for abdom-
inal, thoracic, orthopedic, or cardiac procedures. The 30-
day stroke or systemic embolism rate of 0.36%, although
similar in both the rivaroxiban and warfarin groups
(0.30% vs 0.41%; hazard ratio, 0.74; confidence interval,diovascular Surgery c Volume 148, Number 3 e181
Clinical Guidelines Frendl et al0.36-1.5; P ¼ .4) was higher than the overall rate of 2.2%/
year throughout the study.
In the ROCKET AF study,156 bridging of anticoagula-
tion for temporary interruptions was tracked, and only
6% of the temporary interruptions were bridged, 98.6%
with LMWH and 1.4% with fondaparinux. The bridge
group was slightly older (74 vs 73 years; P ¼ .019), had
a fractionally higher CHADS2 score (3.52 vs 3.40;
P ¼ .0094), more often had diabetes (48% vs 41%;
P ¼ .0049), and had more temporary interruptions. The
rates of previous stroke, transient ischemic attack, and
congestive heart failure in the bridge group were similar
to the rates in the nonbridge group. The bridged patients
had only 1 stroke/embolic event, a 30-day rate of
0.17%, whereas the nonbridge group 30-day event rate
was 0.37%. Major bleeding was similar in both groups,
but the bridged group had a higher incidence of major/
nonmajor clinically relevant bleeding (4.83% vs 3.02%).
Because of the small numbers and variable reasons for
bridging, statistical significance was not calculated. These
data raise the concern that discontinuation of anticoagula-
tion may expose patients to a small but significant risk of
stroke.
Additional data that suggest the importance of consid-
ering the risk of stroke when contemplating the temporary
interruption of anticoagulation were derived from data
obtained after the closing of the ROCKET AF trial. After
cessation of the study medication, the patients on rivaroxi-
ban required an average of 13 days to achieve a therapeutic
INR, whereas the patients receiving warfarin required
only 3 days. The rivaroxiban group had 22 embolic events
and the warfarin group had 7 events over 31 days of
follow-up.157FIGURE 8. Management of anticoagulation for postoperative atrial fibrillatio
INR, international normalized ratio.
e182 The Journal of Thoracic and Cardiovascular SurThe full role of perioperative bridging will be further
elucidated in 2 ongoing randomized trials: BRIDGE (Effec-
tiveness of Bridging Anticoagulation for Surgery; http://
clinicaltrials.gov) and PERIOP-2 (a double-blind, random-
ized, controlled trial of postoperative LMWH bridging ther-
apy vs placebo bridging therapy for patients who are at high
risk for arteriothromboembolism; http://clinicaltrials.gov).7. Management of Anticoagulation for New-Onset
POAF
In order to minimize the risk of perioperative bleeding
whereas/although providing sufficient protection from the
POAF-related strokes a careful evaluation of the patients’
stroke risk is essential. The recently approved novel oral
anticoagulants (NOAC; direct thrombin inhibitors and
anti-Factor Xa agents) offer alternatives to warfarin, and
are gaining popularity in the community for the long-term
management of AF-related anticoagulation.
Recommendations
Class I
7.1. For the prevention of strokes for patients who develop
POAF lasting longer than 48 hours, it is recommended
that antithrombotic medications are administered
similarly to nonsurgical patients (Figure 8). The deci-
sion to initiate therapy should be based on the benefit
of reducing stroke risk versus the risk of bleeding in
the postoperative period33,158-160 (LOE A).
7.1.1. For effective anticoagulation, an INR range of
2 to 3 (with a target of 2.5) for warfarin is
recommended unless otherwise contraindi-
cated161,162 (LOE A).n (POAF) lasting longer than 48 hours. NOACs, New oral anticoagulants;
gery c September 2014
Frendl et al Clinical Guidelines7.1.2. The INR should be determined at least weekly
during initiation of therapy and monthly when
the doses of anticoagulant and the INR are
stable163-165 (LOE A).
Reasoning
The overall risk of a perioperative stroke in all patients
undergoing anesthesia has been estimated at 0.5% to
0.8% in large studies of patients who have had noncardiac
surgery.166,167 One of these studies use the Nationwide
Inpatient Sample of 131,067 patients and determined
that among 39,339 patients undergoing pulmonary
lobectomy/segmentectomy, the incidence of acute
ischemic stroke was 0.6%, which rose to 0.8% for
patients more than 65 years of age.166 Risk factors associ-
ated with perioperative stroke in that study were renal dis-
ease, atrial fibrillation, history of stroke, and cardiac
valvular disease.166 Mortality in patients who developed
a stroke after lung resection was 33% compared with
3.2% in those who did not.166 The reported incidence of
stroke or transient neurologic injury of 1.6% to 3.3% after
cardiac operations is consistently greater for patients who
develop persistent postoperative AF compared with 0.2%
to 1.4% for those without AF.168 It has been established
that oral anticoagulation with warfarin is associated with
60% to 70% reduction from the 4% to 5% overall risk
of ischemic stroke per year in patients with persistent or
chronic nonvalvular AF not receiving warfarin43,159,160,169
Depending of the type of surgery (total hip replacement,
hemicolectomy, or lung resection), 12% to 33% of
arterial thromboembolic events are fatal and more than
40% result in serious permanent disability.158,160 On the
other hand, 3% of episodes of major postoperative
bleeding are fatal but most patients make a full
recovery. As many as 50% of bleeding episodes require
a reoperation.158 A retrospective study of patients who
developed new-onset AF after general thoracic surgery
compared patients that received some form of antithrom-
botic therapy for AF with those who did not receive anti-
coagulation and found that the stoke rate among patients
who were anticoagulated was 2.2% compared with
0.6%, and these patients had a greater incidence of
bleeding episodes.169 In that study, patients who were anti-
coagulated had more comorbidities and greater risk score
for stroke. Whether individuals require short-term antico-
agulation must be individualized for each patient based on
the intrinsic risk for thromboembolism and the risk of
bleeding43,159,160 For most types of surgery, initiation or
resumption of warfarin can be undertaken 12 to 24
hours after surgery unless the patient is at special risk
for bleeding, such as those with a low platelet count,
prolonged excessive chest drainage, or those who might
require an invasive procedure within days or weeks of
discharge (eg, developing an anastomotic leak afterThe Journal of Thoracic and Caresophagectomy).43,158-160,169 These latter patients may
better be managed by LMWH and/or by a TEE-guided
fast-track strategy to rule out an LAA thrombus and
then receive DC cardioversion.159,160,168 Because the
potential for thromboembolism with new-onset AF de-
velops early, prompt attempts to restore sinus rhythm
within this period should be made. If the arrhythmia per-
sists beyond 24 to 48 hours, anticoagulant therapy should
be considered after weighing the risk of postoperative
bleeding. In a prospective study of 330 patients undergo-
ing anatomic lung resection, 1 of 60 patients (1.7%)
with postoperative AF developed a stroke within 24 hours
of onset of AF and Holter monitoring later showed that the
initial 12 hours of AF were asymptomatic.36 Others have
questioned the 48-hour window and suggest that it might
be reasonable to start anticoagulation therapy in the first
48 hour if multiple risk factors for stroke are present.
They further suggest that a TEE-guided strategy may
prove useful in situations where both the risk of stroke
and the risk of postoperative bleeding pose a dilemma
regardless of the fact that AF was not present for 48
hours.170
The goal of anticoagulation should balance the risk of
stroke and the risk of bleeding. The range should be
optimal for adequate stroke prevention but at the same
time should be at the minimal bleeding threshold. In AF,
an INR range of 2.0 to 3.0 with a target of 2.5 should
fulfill this requirement.171 Randomized control studies
have shown that warfarin therapy with an INR of 2.0 to
3.0 was associated with improved outcome compared
with aspirin.172 Hylek and colleagues161 retrospectively
studied 13,559 patients with nonvalvular AF and showed
that an INR less than 2 at admission was associated with
an increased number of strokes. Recently, in the Random-
ized Evaluation of Long-Term Anticoagulation Therapy
(RE-LY) trial, a randomized controlled trial, compared
the outcomes of warfarin versus dabigatran treatment in
AF patients. Warfarin was managed with a target INR of
2.0 to 3.0 and the maximum interval between INR tests
was 4 weeks. They used an algorithm to manage the
INR; for example, þ15% dose/wk increase for INR less
than 1.5, þ10% dose/wk increase for INR from 1.5 to
1.99, 10% dose/wk decrease for INR from 3.01 to
4.00. Implementation of this algorithm resulted in an in-
crease in time in therapeutic range (TTR).162
For in-hospital patients on warfarin, INR is measured
every day until it is therapeutic. For outpatient follow-up,
INR is followed every few days until it reaches the stable
therapeutic target, then the interval can be prolonged as
long as 4 to 6 weeks. The frequency of follow-up depends
on patient compliance, drug and food interactions, interrup-
tion for surgical procedures, and existence of other comor-
bidities.163 Its frequency should be increased when
switching over to another type of anticoagulant, such as adiovascular Surgery c Volume 148, Number 3 e183
FIGURE 9. Considerations for the management of anticoagulation within the first 48 hours of postoperative atrial fibrillation (POAF).
Clinical Guidelines Frendl et alheparin bridge. Pengo and colleagues164 randomized 124
patients to 4-week-interval and 6-week-interval follow-up
of INR testing for patients with prosthetic mechanical
valves and showed that there was no difference in their
TTR. In a randomized study of 250 patients receiving
warfarin, followed at 4-week intervals versus 12-week in-
tervals with phone follow-up every 4 weeks, Schulman
and colleagues165 showed that the 12-week-interval group
had similar TTR and bleeding/embolic events. The Amer-
ican College of Chest Physicians recommends a follow-up
interval of up to 12 weeks if INR is stable.163Recommendations
Class I
7.2. Anticoagulation within the first 48 hours of POAF
(Figure 9) should be considered based on the
CHA2DS2-VASc risk score (Figure 10) of the patient
for stroke weighed against the risk of postoperative
bleeding (LOE C).
7.2.1. For risk assessment, the following may serve as a
guide: CHA2DS2-VASc risk score (Figure 10) for
stroke2,147 (LOE A):FIGURE 10. Stroke risk stratification in atrial fibrillation. From: Lip GY,
Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratifi-
cation for predicting stroke and thromboembolism in atrial fibrillation us-
e184S ¼ 0: no anticoagulation recommended
S ¼ 1: anticoagulation should be considered if its
benefits outweigh the risk of bleeding
S ¼ 2: anticoagulation is highly recommended if
its benefits outweigh the risk of bleedinging a novel risk factor-based approach: the euro heart survey on atrial
fibrillation. Chest. 2010;137:263-72. HTN, Hypertension; MI, myocardial
infarction; PAD, peripheral arterial disease.7.2.2. The presence of impaired renal function should
weigh in favor of anticoagulation. Caution should
be exercised when patients on dialysis are consid-The Journal of Thoracic and Cardiovascular Surered for anticoagulation because the benefits
for those patients are less certain2,3,173-176
(LOE A).
7.2.3. If not precluded by concerns for bleeding, antico-
agulation is also recommended when conversion
to sinus rhythm is attempted by (DC or chemical)
cardioversion (as see section 5.6)2,3,43,159,160
(LOE C).
Reasoning
Since the analysis by the Atrial Fibrillation Investigators
(AFI) of the first 5 prospective, randomized, clinical trials
comparing oral anticoagulants with placebo and sometimes
with aspirin, we have learned that not all patients with atrial
fibrillation have the same risk of stroke177,178 The AFI
demonstrated that stroke risk may be stratified by several
factors, including a previous thromboembolic event orgery c September 2014
Frendl et al Clinical Guidelinestransient ischemic attack, hypertension, diabetes,
congestive heart failure, poor left ventricular function,
and age 65 years or older. Stroke risk was further
stratified to mild, moderate, and severe categories. Other
risks such as coronary artery disease, peripheral vascular
disease, gender, thyrotoxicosis, rheumatic mitral valve
disease, and hypertrophic cardiomyopathy were also
important risk markers to consider.
To translate these risks derived from group data to
the individual, there are now several stroke risk stratifica-
tion schemes available. Initially, most guidelines adopted
the CHADS2 stroke risk stratification scheme, and it has
been widely used for many years.2,3 Recently, the
CHA2DS2-VASc stroke risk stratification scheme
(Figure 10) has taken prominence, having being adopted
by the European Society of Cardiology, and the American
College of Cardiology Foundation/American Heart Asso-
ciation/Heart Rhythm Society guidelines.2,3,147 A major
reason for its use is that it is better at sorting out those
patients with low stroke risks who do not really need
anticoagulation for prophylaxis and those who do. Thus,
a CHADS2 score of 0 or 1 is associated with an annual
risk of 1.9% to 2.8%, not really small risks at all.
However, when applying the CHA2DS2-VASc stroke risk
scheme to the same patients, the CHA2DS2-VASc score
is anywhere from 0 to 4. A CHA2DS2-VASc score of 3
or 4 carries an indication for use of anticoagulation
therapy, whereas a CHA2DS2-VASc score of 0 does
not. A CHA2DS2-VASc score of 1 carries the
recommendation to consider the use of anticoagulation
therapy.
The recommendations using the CHA2DS2-VASc score
are that if the CHA2DS2-VASc score is 0, the patient doesTABLE 8. Commonly used anticoagulants
Drug Mechanism Half life (h) Mode of clearance
Warfarin Vitamin K antagonist Up to 40 Hepatically
metabolized
Dabigatran Thrombin inhibitor 13 Renal
Rivaroxaban Factor Xa inhibitor 7-11 Renal/hepatobiliary
Apixaban Factor Xa inhibitor 12.7 Renal/fecal
INR, International normalized ratio; CrCl, creatinine clearance; P-gp, P-glycoprotein; CY
The Journal of Thoracic and Carnot require anticoagulation. For a CHA2DS2-VASc score
of 1, oral anticoagulation could be considered, and for a
CHA2DS2-VASc of 2 or more, oral anticoagulation is
generally indicated.147 Although the recently published
American College of Cardiology Foundation/American
Heart Association/Heart Rhythm Society AF guidelines
suggested that for a CHADS-VASC score of 1, it is rea-
sonable to consider not using antithrombotic therapy or
aspirin if the burden of cardiovascular disease is otherwise
low.2,3 However, most thoracic surgical patients who
develop (or have) AF would likely have an indication
for anticoagulation using the CHA2DS2-VASc risk
scoring system. Because of its ease of use, and its wide
acceptance, the use of the CHA2DS2-VASc score is
recommended for the assessment of stroke risk.
Several scoring systems have been reported to identify
the risk of bleeding after the initiation of anticoagula-
tion.173-175 These scoring systems are not recommended
for routine use as standard practice. However, among the
risk factors, end-stage renal disease on hemodialysis is
considered to pose a significant risk for bleeding when these
patients are anticoagulated. In a retrospective review of
1626 dialyzed patients and nondialyzed patients, anticoagu-
lation for dialyzed patients did not decrease the risk of
stroke, but increased the incidence of bleeding episodes
with 44%.176
Recommendations
Class IIa
7.3. New oral anticoagulants (dabigatran, rivaroxiban,
apixiban179-182) are reasonable as an alternative to
warfarin (Table 8) for patients who do not have aRecommended doses Significant limitations Ref
Variable (monitor INR) Multiple food and drug
interactions, need for
frequent INR monitoring
and dose adjustments
2,3,147
150 mg twice a day 75 mg
twice a day for CrCl
30-50 mL/min
Interaction with inhibitors of
P-gp, no established
antidote, not recommended
in severe renal failure
2,3,173
20 mg daily, 15 mg daily for
CrCl 15-50 mL/min
Interaction with inhibitors of
P-gp and CYP3A4, no
established antidote, not
recommended in severe
renal failure
2,3,173
5 mg twice a day 2.5 mg twice
a day (AF) for at least 2 of
the following: age>80 y,
body weight<60 kg, Cr
>1.5 mg/dL
Interaction with inhibitors of
P-gp and CYP3A4, no
established antidote, not
recommended in severe
renal failure
2,3,173
P3A4, cytochrome P450 3A4; AF, atrial fibrillation; Cr, serum creatinine.
diovascular Surgery c Volume 148, Number 3 e185
Clinical Guidelines Frendl et alprosthetic heart valve, hemodynamically significant
valve disease, and/or severe renal impairment or risk
of gastrointestinal bleeding2,157,183,184 (LOE B).
7.4. It is reasonable to continue anticoagulation therapy for
4 weeks after the return of sinus rhythm because of the
possibility of slowly resolving impairment of atrial
contraction with an associated ongoing risk for
thrombus formation and for delayed embolic
events43,159,160 (LOE C).
Reasoning
Newer oral anticoagulant drugs have recently become
available, including dabigatran, rivaroxaban, and apixa-
ban. Dabigatran is an oral direct thrombin inhibitor,
whereas rivaroxaban and apixaban are factor Xa inhibi-
tors. Compared with warfarin, these agents offer the
advantage of not requiring monitoring of the INR. The ef-
ficacy of dabigatran for stroke prevention in nonsurgical,
nonvalvular AF was compared with that of warfarin in
the RE-LY trial,183 which was a prospective noninferiority
study that randomized 18,113 patients into 3 groups: dabi-
gatran 110 mg twice daily or dabigatran 150 mg twice
daily, administered in blinded fashion, or warfarin titrated
to an INR of 2.0 to 3.0, administered in unblinded fashion
for a median duration of 2 years. Dabigatran 150 mg twice
daily significantly reduced the risk of stroke or systemic
embolism by 34% compared with warfarin. There was
no significant difference in the incidence of death in either
dabigatran group compared with the warfarin-treated
group. There was no difference in the incidence of major
bleeding between the groups on warfarin and dabigatran
150 mg twice daily. However, there was a significantly
lower incidence of hemorrhagic stroke in dabigatran 150
mg twice daily group compared with the warfarin group.
The efficacy of rivaroxaban for reducing risk of stroke
in patients with nonsurgical, nonvalvular AF was
compared with that of warfarin in the ROCKET AF
trial.157 In this noninferiority study, 14,264 patients with
AF were randomized in double-blind fashion to receive ri-
varoxaban 20 mg orally daily or warfarin titrated to an
INR of 2.0 to 3.0 for a median treatment period of 590
days (median follow-up, 707 days). Compared with
warfarin, rivaroxaban significantly reduced the risk of
stroke or systemic embolism by 21%. Using an
intention-to-treat analysis, there was no significant differ-
ence between rivaroxaban and warfarin in the incidence
of stroke or systemic embolism. There was no difference
between the groups in the incidence of major and
nonmajor clinically relevant bleeding. However, the inci-
dence of intracranial hemorrhage and fatal bleeding was
significantly lower in rivaroxaban-treated patients. The ef-
ficacy of apixaban compared with that of warfarin for
stroke prevention in nonsurgical, nonvalvular AF wase186 The Journal of Thoracic and Cardiovascular Surinvestigated in the Apixaban for Prevention of Stroke in
Subjects with Atrial Fibrillation (ARISTOTLE) noninfer-
iority trial.184 Patients (n ¼ 18,201) with AF and at least
1 additional risk factor for stroke were randomized to
receive apixaban 5 mg orally twice daily or warfarin
titrated to an INR of 2.0 to 3.0 for a median follow-up
of 1.8 years. The risk of ischemic or hemorrhagic stroke
or systemic embolism in the apixaban group was signifi-
cantly lower than in the warfarin group, as was the inci-
dence of death from any cause. The incidences of major
bleeding and hemorrhagic stroke were also significantly
lower in apixaban-treated patients. There was no
difference between the groups in the incidence of ischemic
or uncertain type of stroke.
Patients who received standard anticoagulation on
discharge from the hospital can return for cardioversion
between 3 and 12 weeks after initiation of anticoagulant
therapy43,158,168 Patients who convert to sinus rhythm but
are experiencing intermittent paroxysms of AF may be
considered for anticoagulation for 1 month after the return
of sinus rhythm because it has been shown that impaired
atrial mechanical function can persist for several weeks
after the return of sinus rhythm.43,159
Recommendations
Class III
7.5. New oral anticoagulants should be avoided for patients
at risk for serious bleeding (including gastrointestinal
bleeding) as they cannot be readily reversed. However,
their use may be recommended in situations where
achievement of a therapeutic INR with warfarin has
proved to be difficult185 (LOE C).
Reasoning
A large phase 2 randomized control study, the RE-
ALIGN trial, studied patients who underwent implanta-
tion of mechanical valve (aortic or mitral) or had
undergone implantation of mitral bileaflet valve less
than 3 months before randomization.185 The trial was
terminated because of an increase in strokes (5% vs
0%), myocardial infarction, and major bleeding (4% vs
2%) in the dabigatran group. Currently, dabigatran is
contraindicated and should not be used in patients with
mechanical valves.8. Recommendations for Long-Term Management
and Follow-up of PatientsWith Persistent New-Onset
POAF
Those patients with POAF-related perioperative
complications, and those requiring long-term management
of antiarrhythmics and anticoagulants are likely to
benefit from cardiology follow-up after their discharge
(Figure 11).gery c September 2014
FIGURE 11. Recommendation for the postdischarge follow-up for patient with new onset postoperative atrial fibrillation (POAF). Post-op, Postoperative;
EF, ejection fraction; NSR, normal sinus rhythm; ECG, electrocardiography.
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8.1. Postdischarge follow-up and management recom-
mendations for persistent new-onset POAF.Class I
8.1.1. For patients who have a complicated in-hospital
course related to their POAF, who have underlying
structural heart disease, or who experience
sequelae of AF, such as myocardial infarction or
decreased LVEF, follow-upwith cardiology should
be arranged at the time of discharge (LOE C).
Class IIb
8.1.2. Patients with well-controlled new-onset POAF
(either converted to sinus rhythm or with good
rate control) may be seen in routine follow-up
by the surgical team without cardiology follow-
up (LOE C).
Reasoning
Most cases of POAF are self-limiting and even when pre-
sent at discharge, will have resolved by the time of follow-
up. There is little literature regarding postdischarge risks for
general thoracic patients specifically. Recommendations
regarding cardiology follow-up for complicated patients
seem self-evident. The appropriate timing for cardiology
follow-up should be individualized before discharge. For
uncomplicated patients, there is some evidence for guid-
ance. After lung resection, Rena and colleagues104 demon-
strated that 98% of POAF resolved after discharge,The Journal of Thoracic and Caralthough this was as an older study, 80% were given digi-
talis. The duration was between 1 and 12 days, with an
average of 2 days. It has been estimated that approximately
50% of episodes of POAF spontaneously convert to normal
sinus rhythm within 12 hours.186 Given the relatively short
duration of POAF in most cases, it is unclear when the first
postoperative visit to the surgeon in uncomplicated cases
should be. The 2010 guidelines of the Canadian Cardiovas-
cular Society recommend that medical management of AF
and anticoagulation should be reassessed at 6 to 12 weeks
postoperatively, although this was intended primarily for
cardiac surgical patients. This was considered a strong
recommendation, with moderate evidence but no reference
was given.187 Kowey and colleagues188 reported a retro-
spective analysis of 116 patients with POAF after coronary
bypass surgery. There were 36 patients treated with antiar-
rhythmic and rate control drugs compared with 76 treated
with rate control agents alone. Only 1 patient in each group
was still in AF at 6-week follow-up. In another study, Izhar
and colleagues189 randomized 129 patients after coronary
bypass surgery who had converted to sinus rhythm before
discharge to 1, 3, or 6 weeks of antiarrhythmic therapy.
There was no difference in the rate of recurrent AF with
0, 2, and 0 patients in the 3 groups. Most of the patients
were managed with amiodarone. On this basis, it seems
reasonable that the timing of routine surgical follow-up
should be dictated by surgical considerations, and the pres-
ence or absence of AF assessed at that time.diovascular Surgery c Volume 148, Number 3 e187
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of POAF, the long-term significance of a single episode of
POAF is unknown.190 Ahlsson and colleagies190 studied
the late outcome of patients who developed POAF after cor-
onary bypass surgery and found that the development of AF
was a risk factor for late mortality. Whether this applies to
patients after noncardiac thoracic surgery is unknown.
However, it seems prudent to ensure communication with
the primary care physician for vigilant follow-up of cardio-
vascular and AF risk factors.
Recommendations
8.2. Management of antiarrhythmic medications
Class IIa
8.2.1. For patients who have converted to sinus rhythm
before hospital discharge, it is reasonable to
consider discontinuation of antiarrhythmic medi-
cations 4 weeks after ECG documented return of
normal sinus rhythm or at the first postoperative
visit (usually 2-6 weeks after discharge) (LOE C).
Class IIb
8.2.2. For patients with new-onset POAF who were dis-
charged in AF but who are in normal sinus rhythm
(ECG confirmed) at the first postoperative visit, it
may be reasonable to instruct the patients to
self discontinue the antiarrhythmic medications
4 weeks after the visit if no signs of AF recur
(LOE C).
Reasoning
There is no clear evidence to guide duration of antiar-
rhythmic therapy after noncardiac thoracic surgery. Landy-
more and colleagues191 followed 58 patients who
underwent coronary artery bypass grafting with ambulatory
Holter monitoring, including 3 patients who developed
spontaneous symptomatic AF and received digitalis for
rate control. Sixteen patients (group 2) continued taking
digoxin for 8 weeks after surgery, 13 patients (group 3)
discontinued digoxin treatment 5 weeks after surgery, and
14 patients (group 4) discontinued digoxin treatment
3 weeks after surgery. Twenty-four–hour Holter monitoring
indicated that asymptomatic AF was common in the treat-
ment groups after digitalization just before discharge from
hospital. Recurrence of AF was rare after discharge. Yilmaz
and colleagues192 performed a similar smaller study, with
120 patients who had converted to sinus rhythm (pharma-
cologically or with DC cardioversion) enrolled in a prospec-
tive randomized trial of placebo or 1 of 3 drugs (amiodarone,
verapamil, or quinidine) postdischarge. Patients underwent
24-hour Holter monitoring 6 times over 9 months postopera-
tively. Recurrent AF usually developed within 15 days of
discharge. AF occurred in only 1 patient (3.33%) in group
1, and 2 each (6.66%) in each of the drug groups.e188 The Journal of Thoracic and Cardiovascular SurRecommendations
8.3. Management of anticoagulation
Class I
8.3.1. For patients who are started on anticoagulants, the
anticoagulation should continue for a minimum
of 4 weeks after return to normal sinus rhythm
is documented (LOE C).
Class IIa
8.3.2. More prolonged anticoagulation (longer than
4 weeks after return to normal sinus rhythm)
can be beneficial in the presence of stroke risk
factors (CHA2DS2-VASc score) or if the patient
had a previous stroke. The concomitant presence
of mild or moderately impaired kidney function
weighs in favor of a longer period of anticoagula-
tion (LOE B).
8.4. Recommendations for long-term management of
new-onset persistent POAFClass IIa
8.4.1. Patients with new-onset POAF persisting for or
recurring after 4 to 6 weeks (or at the time of
the first postoperative visit) can benefit from
referral to a cardiologist for long-term manage-
ment of stroke risk as well as antiarrhythmic or
anticoagulant medications (LOE C).
Reasoning
The ideal duration of anticoagulation after POAF is un-
known. European guidelines have concluded that there is
insufficient evidence to make any recommendation.193
Others have concluded that it is reasonable to continue anti-
coagulation for 4 weeks, on the basis that atrial contraction
is impaired long after the AF has ceased.4 All the current
evidence in this area is level C.
RECOMMENDATIONS FOR FUTURE AATS
EFFORTS
The task force recommends the establishment of a high-
fidelity thoracic surgery database that uses the uniform
definitions and monitoring strategies recommended here,
stratifies by surgery type, and systematically documents
the occurrence, duration, and complications of POAF and
its treatment. The aim would be to develop risk prediction
models, and eventually randomized interventional trials,
for the prevention and treatment of POAF, specific to
thoracic surgery. This could be most readily accomplished
by enriching the STS data collection system.
RECOMMENDATIONS FOR THE USE OF THE
GUIDELINES
These guidelines are best used as a guide for practice and
teaching. The applicability of these recommendations to thegery c September 2014
Frendl et al Clinical Guidelinesindividual patient should be evaluated on a case-by-case ba-
sis, and only applied when clinically appropriate. In addi-
tion, these guidelines can serve as a tool for uniform
practices, to guide preoperative evaluations, and form the
basis of large, multicenter cohort studies for the thoracic
surgical community.
The task force received no financial support. AATS
provided teleconferencing and covered the cost of a 1-day
face-to-face conference for the participants. The members
of this task force had no conflicts of interest related to any
of the 88 recommendations made here; all their other poten-
tial conflicts of interest were disclosed in writing (Online
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